DECEMBER 10-13, 2019
9TH EDITION
HIV PERSISTENCE DURING THERAPY®
Reservoirs & Eradication Strategies Workshop

FINAL PROGRAM

Florida Miami USA
www.hiv-persistence.com
DECEMBER 2021
10th Edition
HIV PERSISTENCE DURING THERAPY
Reservoirs & Eradication Strategies Workshop

FLORIDA MIAMI USA

www.hiv-persistence.com
**Steering Committee**

Alain Lafeuillade, MD  
Infectious disease private practice, La Valette du Var – FRA

David Margolis, PhD  
University of North Carolina, Chapel Hill – USA

Karl Salzwedel, PhD  
National Institute of Allergy and Infectious Diseases, Bethesda – USA

Mario Stevenson, PhD  
University of Miami Leonard M. Miller School of Medicine, Miami – USA

**Scientific Committee**

José Alcami, Madrid – ESP  
Monsef Benkirane, Montpellier – FRA  
Nicolas Chomont, Montreal – CAN  
Tae-Wook Chun, Bethesda – USA  
Janice Clements, Baltimore – USA  
John Coffin, Boston – USA  
Steven Deeks, San Francisco – USA  
J. Víctor García-Martínez, Chapel Hill – USA  
Romas Geleziunas, Foster City – USA  
Warner Greene, San Francisco – USA  
George Hanna, Princeton – USA  
Daria Hazuda, West Point – USA  
Jacques Izopet, Toulouse – FRA  
Rowena Johnston, New York City – USA  
Jonathan Karn, Cleveland – USA

Richard Koup, Bethesda – USA  
Guenter Kraus, Beerse – BEL  
Sharon Lewin, Melbourne – AUS  
Javier Martinez-Picado, Badalona – ESP  
John W. Mellors, Pittsburgh – USA  
Sarah Palmer, Sydney – AUS  
Vicente Planellés, Salt Lake City – USA  
Guido Poli, Milan – ITA  
Christina Psomas, Montpellier – FRA  
Douglas Richman, La Jolla – USA  
Jean-Pierre Routy, Montreal – CAN  
Andrea Savarino, Rome – ITA  
Robert Siliciano, Baltimore – USA  
Carine Van Lint, Gosselies – BEL  
Jan Van Luzen, London – UK
Dear Colleagues,

Welcome to the ninth International Workshop on HIV Persistence during Therapy. Since the first edition of this workshop in 2003 in St Maarten, the issues of HIV Persistence and reservoirs have become increasingly more relevant, not only for the biologist but also for the clinician facing the problem of the long-term control of this persistent retroviral infection.

Several meetings have now included reviews on these topics in their program, but this biennial workshop is unanimously recognised as the reference workshop on HIV reservoirs and eradication strategies.

Our main objective is to keep it driven by science and new data. To this end, abstracts have undergone a rigorous selection procedure by the Scientific Committee.

This year’s Workshop has focused on improving participation by young investigators, in particular through submitting oral or poster abstracts, but also through receiving grants for attendance. These scholarships have been made possible by both the National Institutes of Health and the Steering Committee involvement. We all are all very grateful for this development that we hope will bring new energy, thinking and ideas to the field.

The program format will continue to follow the past successes and include presentations of new, unpublished data and a panel of experts to sum up the current advances in the field.

Lastly, we thank all the participants who have chosen to present their work here: the excellence of the abstracts we have received undoubtedly guarantees and interesting and thought-provoking workshop.

We wish you all an enjoyable and fruitful workshop.

Alain Lafeuillade, MD, Chairman,

On behalf of the Steering Committee
<table>
<thead>
<tr>
<th>Time</th>
<th>TUESDAY, DECEMBER 10</th>
<th>WEDNESDAY, DECEMBER 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td></td>
<td>SESSION 1: Basic Science of HIV Latency</td>
</tr>
<tr>
<td>9:00 AM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>NIMH Satellite Symposium: CNS and Myeloid Cell Reservoirs</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Meeting of the Martin Delaney Collaboratories Community Advisory Board HIBISCUS ISLAND ROOM</td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30 AM</td>
<td>12:30 PM</td>
<td>SESSION 2: In Vitro and Animal Model Studies of HIV Persistence</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Lunch on your own</td>
<td>Lunch</td>
</tr>
<tr>
<td>2:00 PM</td>
<td></td>
<td>SESSION 3: Virology of HIV Persistence</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>NIAID satellite symposium: Martin Delaney Collaboratories research highlights (SESSION 1)</td>
<td></td>
</tr>
<tr>
<td>3:30 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td>NIAID satellite symposium: Martin Delaney Collaboratories research highlights (SESSION 2)</td>
<td></td>
</tr>
<tr>
<td>5:30 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30 PM</td>
<td>Opening Lecture</td>
<td></td>
</tr>
<tr>
<td>7:30 PM</td>
<td>Welcome Dinner</td>
<td>Dinner on your own</td>
</tr>
<tr>
<td>7:30 PM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# AT A GLANCE

<table>
<thead>
<tr>
<th>THURSDAY, DECEMBER 12</th>
<th>FRIDAY, DECEMBER 13</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SESSION 4:</strong> Immunology of HIV Persistence</td>
<td><strong>SESSION 7:</strong> Human studies and drug development II</td>
</tr>
<tr>
<td><strong>Coffee Break</strong></td>
<td><strong>Closing Ceremony</strong></td>
</tr>
<tr>
<td><strong>SESSION 5:</strong> Human studies and drug development I</td>
<td><strong>SESSION 8:</strong> New Therapeutic Approaches II</td>
</tr>
<tr>
<td><strong>Lunch</strong></td>
<td></td>
</tr>
<tr>
<td><strong>SESSION 6:</strong> New Therapeutic Approaches I</td>
<td><strong>ALL THE SESSIONS WILL BE IN THE MAIN PLENARY SESSION ROOM (SALON A TO E).</strong></td>
</tr>
<tr>
<td>with wine and cheese tasting</td>
<td></td>
</tr>
<tr>
<td><strong>Dinner on your own</strong></td>
<td></td>
</tr>
</tbody>
</table>

*All the sessions will be in the Main Plenary Session Room (Salon A to E).*
TUESDAY, DECEMBER 10, 2019

09:00 - 12:00

NIMH SATELLITE SYMPOSIUM: CNS AND MYELOID CELL RESERVOIRS

Chairs: Jeymohan JOSEPH, Division of AIDS Research, NIMH - USA
Mario STEVENSON, University of Miami - USA

09:00 - 09:15

Session Goals and NIMH Research Priorities in CNS and Myeloid Reservoirs

Jeymohan JOSEPH, AIDS Research, NIMH - USA

09:15 - 09:30

Unexpected Outcomes in the Rebound Zone: Utilizing Correlative PET/CT and Multi-Scale Imaging to Define SIV Rebound After ART Cessation

Thomas HOPE, Northwestern University - USA

09:30 - 09:45

Macrophage-tropic HIV-1 variants populate plasma viremia in chronic and acute subjects undergoing analytic treatment interruption

Viviane MACHADO, University of Miami - USA

09:45 - 10:00

Evidence of HIV Persistence in Circulating Myeloid Cells: Implications for HIV-associated Complications and Remission

Brooks MITCHELL, University of Hawaii at Manoa - USA

10:00 - 10:15

Genetic and functional differences in the CNS vs systemic HIV-1 reservoirs

Maria GONZALEZ PAZ, University of Massachusetts Medical School - USA

10:15 - 10:30

HIV-infected macrophages evade NK cell-mediated killing while driving inflammation

Kiera CLAYTON, Ragon Institute - USA

10:30 - 11:00 AM Break

11:00 - 11:15

Targeting IncRNA SAF to induce apoptosis in HIV-1 infected macrophages

Tsaikat BOLIAR, Cornell University - USA

11:15 - 11:30

Low-level Persistent/Latent HIV-1 Infection of Macrophages Correlates to Decreased NF-kB Activity

Tim HANLEY, University of Utah Health Sciences Center - USA

11:30 - 11:45

Effects of Blocking NOX Signaling on HIV Persistence and HIV-associated Neurocognitive Dysfunction in a Murine HAND Model

Christina GAVEGNANO, Emory University - USA

11:45 - 12:00

Detection and modulation of HIV reservoirs in HIV infected patients on ART

Avi NATH, NIH - USA
**MEETING OF THE MARTIN DELANEY COLLABORATORIES COMMUNITY ADVISORY BOARD**

**HIBISCUS ISLAND ROOM**

**NIAID SATELLITE SYMPOSIUM: MARTIN DELANEY COLLABORATORIES RESEARCH HIGHLIGHTS (SESSION 1)**

**DARE Collaboratory**

**Introduction**

Steven DEEKS, University of California, San Francisco - USA

Engaging CD8+ T cell responses in SIV Reservoir Reduction or Reactivation Control

Afam OKOYE, Oregon Health & Science University - USA

**BEAT-HIV Collaboratory**

**Introduction**

Luis MONTANER, The Wistar Institute - USA

Peripheral Blood SIV/HIV Originates from Infected Cells in Tissues

Leticia KURI-CERVANTES, University of Pennsylvania - USA

Contribution of Antigenic Exposure to the Persistence of HIV-Infected CD4+ T Cells In Vivo

Francesco R. SIMONETTI, Johns Hopkins University - USA

**BELIEVE Collaboratory**

**Introduction**

R. Brad JONES, Weill Cornell Medicine – USA

Combination IL-15 Therapy in a SHIV NHP Model

James B. WHITNEY, Beth Israel Deaconess Medical Center - USA

---

**3:30 - 4:00 PM Coffee Break**

**NIAID SATELLITE SYMPOSIUM: MARTIN DELANEY COLLABORATORIES RESEARCH HIGHLIGHTS (SESSION 2)**

**I4C Collaboratory**

**Introduction**

Dan BAROUCH, Beth Israel Deaconess Medical Center - USA

Origin of Rebound Virus in Chronically SIV-Infected Monkeys Following Treatment Discontinuation

Po-Ting LIU, Beth Israel Deaconess Medical Center - USA

HIV-1 Diversity Considerations for Clinical Studies of Passively Transferred Broadly Neutralizing Antibodies

Kshitij WAGH, Los Alamos National Laboratory - USA
DefeatHIV Collaboratory

**Introduction**
Hans-Peter KIEM, Fred Hutchinson Cancer Research Center - USA

**CAR T Cell-Treated Rhesus Macaques Suppress SHIV Viremia Following ART Treatment Interruption**
Christopher PETERSON, Fred Hutchinson Cancer Research Center - USA

CARE Collaboratory

**Introduction**
David MARGOLIS, University of North Carolina at Chapel Hill - USA

**Novel Bivalent Chemical Degraders to Reverse HIV Latency**
Anne-Marie TURNER, UNC HIV Cure Center, University of North Carolina, Chapel Hill - USA

**Improved Killing of HIV-infected Cells by a Combination of Three Antibodies: Implications for Clearing Persistent Infection**
Marina TUYISHIME, Department of Surgery, Duke University Medical Center, Durham, NC - USA

CanCURE Overview

Eric COHEN, IRCM, Human Retrovirology research unit, Montréal - CAN

---

5:45 - 6:00 PM Break

---

**WELCOME**

Alain LAFEUILLADE, Infectious disease private practice, La Valette du Var - FRA

**Opening Lecture**

**Introduction**
Chairs:
Karl SALZWEDEL, National Institute of Allergy and Infectious Diseases, Bethesda - USA
Alain LAFEUILLADE, Infectious disease private practice, La Valette du Var - FRA

**Ending the HIV Pandemic: Follow the Science**
Anthony S. FAUCI, National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, WA - USA

**Bringing curative interventions for HIV to resource-limited parts of the world**
Mike McCUNE, HIV Frontiers, Global Health Innovative Technology Solutions, Bill & Melinda Gates Foundation - USA

**WELCOME DINNER**
SESSION 1: BASIC SCIENCE OF HIV LATENCY

Chairs: Jonathan KARN, Professor and Chair, Department of Molecular Biology and Microbiology, School of Medicine, Director, Case Center for AIDS Research, Cleveland/Akron, OH - USA
Una O’DOHERTY, Associate Professor Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, PA - USA
Christina PSOMAS, Clinical and Translational Research in the Department of Infectious Diseases of Montpellier University Hospital - FRA

OP 1.0: Cellular Mechanisms that Establish and Maintain HIV Latency
Lecturer: Andrew HENDERSON, Professor of Medicine, Assistant Dean Graduate Medical Sciences Department of Medicine and Microbiology, Section of Infectious Diseases Boston University School of Medicine, Boston, MA - USA

OP 1.1: Expression Profiling of HIV Latently-Infected Cells Using Nanostring And Mass Cytometry
Author(s): H. Sperber 1, 2,*, T. Ma 3, N.R. Roan 3, S.K. Pillai 1
1Vitalant Research Institute - San Francisco (USA)
2Free University of Berlin - Berlin (GER)
3Gladstone Institutes - San Francisco (USA)

OP 1.2: A quantitative single cell, single molecule RNA-FISH + IF and single cell RNA-seq analysis reveals stochasticity of reactivation of latent provirus.
Author(s): G. Kalpana 1,* , R. Pathak 1, A. La Porte 1, E. Bock 1, C. Eliscovich 1, L. Martins 2, A. Spivac 2, U. Díxit 1, V. Planelles 2, R. Singer 1
1Albert Einstein College of Medicine - New York (USA)
2University of Utah School of Medicine - Salt Lake City (USA)

OP 1.3: Single-cell transcriptome sequencing of latently-infected cells ex vivo using PCR-activated cell sorting (PACS).
Author(s): L. Clark 1, 2,*, A. Abate 1, F. Quintana 2, S. Deeks 1, D. Douek 3, E. Boritz 3,*
1UCSF - San Francisco (USA)
2Harvard - Boston (USA)
3NIH - Bethesda (USA)

OP 1.4: Single cell analysis of in vivo HIV reservoir uncovers novel markers of latent cells
Author(s): N. Roan 1,*, Jason Neidleman 1, 8, Xiaoyu Luo 1, Julie Frouard 1, 8, Feng Hsiao 1, 8, Guorui Xie 1, 8, Vincent Morcilla 2, Katherine Sholtis James 3, Rebecca Hoh 4, Ma Somsouk 5, Peter Hunter 6, Steve Deeks 4, Nancie Archin 3, Sarah Palmer 2, Warner C. Greene 1, 7
1Gladstone Institute of Virology and Immunology, San Francisco, CA (USA)
2Centre for Virus Research, the Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW 2145 (AUS)
3Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC (USA)
4Division of HIV, Infectious Diseases and Global Medicine, University of California San Francisco, San Francisco, CA (USA)
5Department of Medicine, Division of Gastroenterology, San Francisco General Hospital and University of California, San Francisco, CA (USA)
6Division of Experimental Medicine, University of California San Francisco, San Francisco, CA (USA)
7Department of Medicine, University of California, San Francisco, CA (USA)
8Department of Urology, University of California, San Francisco, CA (USA)

OP 1.5: Quantifying the contribution of cellular proliferation to maintaining the HIV reservoir
Author(s): A. Hill 1,*, G. Andrei 1, J. Gerold 1
Harvard University - Cambridge, Ma (USA)

OP 1.6: Tyrosine Kinase Inhibition: the new Front in HIV Cure Efforts.
Author(s): V. Planelles 1,*, M. Szaniawski 1, E. Williams 1, E. Innis 1, L. Martins 1, A. Spivak 1, J. Alcami 2, M. Coiras 2
SESSION 2: IN VITRO AND ANIMAL MODEL STUDIES OF HIV PERSISTENCE

Chairs:
Ann CHAHROUDI, Associate Professor of Pediatrics, Division of Pediatric Infectious Diseases, Emory University School of Medicine, Atlanta, GA - USA
Afam OKOYE, Research Associate Professor Vaccine & Gene Therapy Institute, and Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton - USA

► OP 2.0: In vivo platforms for the evaluation of novel approaches to HIV persistence and eradication
Lecturer: J. Victor GARCIA MARTINEZ, Professor of Medicine, Center for AIDS Research, Division of Infectious Diseases, Chapel Hill - USA

► OP 2.1: Understanding the establishment and persistence of the rebound competent reservoir using barcoded viruses
Lecturer: Brandon F. KEELE, AIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick - USA

► OP 2.2: Barcoded viruses facilitate tracking changes to the composition of the rebound-competent reservoir
Author(s): T. Immonen 1,*, C. Fennessey 1, J. Lifson 1, B. Keele 1,*
AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research - Frederick (USA)

► OP 2.3: Delay in Viral Rebound with TLR7 Agonist, N6-LS and PGT121 in SHIV-infected Macaques
Author(s): D. Hsu 1,*, D. Silsorn 2, R. Imerbsin 2, A. Pegu 3, J. Mascola 3, R. Geleziunas 4, R. Koup 3, D. Barouch 5, N. Michael 6, S. Vasan 6
1MHRP - Bangkok (THA)
2AFRIMS - Bangkok (THA)
3NIH - Bethesda (USA)
4Gilead Sciences - Foster City (USA)
5BIDMC - Boston (USA)
6MHRP - Silver Spring (USA)

► OP 2.4: Chimeric Antigen Receptor T-Cells and Stem Cells Control and Protect Against SHIV Replication in Nonhuman Primates
Author(s): C. Peterson 1,*, B. Rust 1, A. Zhen 2, K. Brandenstein 1, N. Poole 1, C. Maldini 3, G. Ellis 3, S. Kitchen 2, J. Riley 3, H.P. Kiem 1
1Fred Hutchinson Cancer Research Center - Seattle (USA)
2University of California, Los Angeles - Los Angeles (USA)
3University of Pennsylvania - Philadelphia (USA)

► OP 2.5: The latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques is potentiated by CD8a cell depletion
Author(s): M. Mavigner 1,*, A. Brooks 1, C. Mattingly 1, T. Vanderford 1, B. Keele 2, J. Lifson 2, R. Dunham 3, D. Margolis 3, G. Silvestri 1, A. Chahroudi 1
1Emory University - Atlanta (USA)
2Frederick National Laboratory for Cancer Research - Frederick (USA)
3UNC Chapel Hill - Chapel Hill (USA)

► OP 2.6: Utilizing correlative PET/CT and multiscale imaging to define the dynamics of SIV infected cells from early ART initiation to the rebound after analytic treatment interruption
Author(s): T. Hope 1,*, M.S. Arif 1, Y. Thomas 1, I. Clerc 1, A. Carias 1, E. Allen 1, M. Mcraven 1, M. Ramirez 2, P. Santangelo 3, F. Villinger 2
1Northwestern - Chicago (USA)
2New Iberia Research Center - New Iberia (USA)
3Georgia Tech - Atlanta (USA)

12:30 - 2:00 PM Lunch
SESSION 3: VIROLOGY OF HIV PERSISTENCE

Chairs:
Katherine BAR, Associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, USA
Zabrina BRUMME, Director, Laboratory Program, BC Centre for Excellence in HIV/AIDS, Saint Paul Hospital, Vancouver - CAN

▶ OP 3.0: CD4-MBL-CAR/CXCR5 T cell immunotherapy shows promise at reducing SIV replication post-ART release
Lecturer: Pamela SKINNER, Professor Department of Veterinary and Biomedical Sciences Microbiology, Immunology and Cancer Biology (MICaB) Ph.D. Graduate Program, University of Minnesota, MN - USA

▶ OP 3.1: Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy
Author(s): M. Peluso 1, P. Bacchetti 1, K. Ritter 2, S. Beg 3, P. Hunt 1, T. Henrich 1, J. Siliciano 3, R. Siliciano 3, G. Laird 2, S. Deeks 1
1University of California, San Francisco - San Francisco (USA)
2Accelevir Diagnostics - Baltimore (USA)
3Johns Hopkins School of Medicine - Baltimore (USA)

▶ OP 3.2: Women undergoing reproductive aging show increased reservoir sizes associated with removal of hormonal control of HIV-1 latency by estrogen
Author(s): J. Kam 1, C. Dobrowolski 1, E. Scully 2, K.M. Weber 3, A.L. Landay 4
1Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine - Cleveland (USA)
2Johns Hopkins University, Department of Medicine, Division of Infectious Diseases - Baltimore (USA)
3WIHS/CORE Center of Cook County Health - Chicago (USA)
4Rush University Medical Center, Department Internal Medicine - Chicago (USA)

▶ OP 3.3: Contribution of Antigenic Exposure to the Persistence of HIV-infected CD4+ T-cells in vivo
Author(s): F. Simonetti 1, H. Zhang 1, G. Soroosh 1, S. Beg 1, H. Raymond 2, K. Mccormick 2, S. Deeks 3, F. Bushman 2, J. Siliciano 4, R. Siliciano 1
1Johns Hopkins University - Baltimore (USA)
2University of Pennsylvania - Philadelphia (USA)
3University of California San Francisco - San Francisco (USA)
4Johns Hopkins University - Baltimore (USA)

▶ OP 3.4: Multiplexed RNA flow cytometric FISH allows single-cell viral transcriptional profiling and phenotypic characterization of translation-incompetent HIV reservoirs
Author(s): M. Dubé 1, D. Kaufmann 1, G. Sannier 1, N. Brassard 1, G.G. Delgado 1, A. Baxter 1, J.P. Routy 2, N. Chomont 1
1Research Centre of the Centre Hospitalier de l’Université de Montréal (CRCHUM) and Université de Montréal, Montreal, Quebec, Canada - Montréal (CAN)
2Chronic Viral Illnesses Service and Division of Hematology, McGill University Health Centre - Montréal (CAN)

▶ OP 3.5: Low Viral Reservoir Treated Individuals Show Unusual HIV Latency Distribution
Author(s): C. Gálvez 1, V. Urrea 1, S. Benet 1, B. Mothe 1, L. Bailón 2, J. Dalmau 1, L. Leal 3, F. García 3, J. Martinez-Picado 1, M. Salgado 1
1AIDS Research Institute IrsiCaixa - Badalona (SPA)
2Infectious Diseases Department, University Hospital “Germans Trias i Pujol” - Badalona (SPA)
3Infectious Diseases Department, Hospital Clinic, University of Barcelona - Barcelona (SPA)

Coffee Break

POSTER VIEWING SESSION WITH WINE AND CHEESE TASTING

DINNER ON YOUR OWN
SESSON 4: IMMUNOLOGY OF HIV PERSISTENCE

Chairs:
Lydie TRAUTMANN, Associate Professor, OHSU, Vaccine & Gene Therapy Institute, Beaverton - USA
R. Brad JONES, Assistant Professor, Department of Medicine, Weill Cornell Medicine, New York, NY - USA

✦ OP 4.0: CellulaT Cells and The Cure Agenda
Lecturer: Bruce WALKER, Founding Director of the Ragon Institute of MGH, MIT and Harvard and the Director of the Harvard University Center for AIDS Research, Cambridge, MA - USA

✦ OP 4.1: HIV persistence during ART: Keeping memory, keeping HIV
Lecturer: Nicolas CHOMONT, Associate Professor in the Department of Microbiology and Immunology at the Université de Montréal – CHUM Research Center, Montreal - CAN

✦ OP 4.2: Characterizing “exceptional” control among HIV elite controllers
Author(s): M. Peluso 1,*, P. Burbelo 2, S. Kumar 1, S. Munter 1, R. Hoh 1, S. Lee 1, P. Hunt 1, R. Rutishauser 1, T. Henrich 1, S. Deeks 1
1University of California, San Francisco - San Francisco (USA)
2National Institutes of Health - Bethesda (USA)

✦ OP 4.3: Single-cell TCR sequencing reveals that clonally expanded cells highly contribute to the inducible HIV reservoir during ART
Author(s): P. Gantner 1,*, A. Pagliuzza 2, M. Pardons 1, M. Ramgopal 3, J.P. Routy 3, R. Fromentin 2, N. Chomont 1
1Université de Montréal - Montréal (CAN)
2CRCHUM - Montréal (CAN)
3Midway Immunology & Research Center - Fort Pierce (USA)

✦ OP 4.4: Single-cell phenotyping of HIV-infected expanded clones in ART-suppressed individuals
Author(s): C. Dufour 1,*, M. Pardons 1, R. Fromentin 1, M. Massanella 1, S. Palmer 2, S. Deeks 3, B. Murrell 4, J.P. Routy 5, N. Chomont 1
1Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Université de Montréal – Montreal (CAN)
2Centre for Virus Research, The Westmead Institute of Medical Research, The University of Sydney - Sydney (AUS)
3Department of Medicine, University of California San Francisco - California (USA)
4Division of Hematology & Chronic Viral Illness Service, McGill University Heath Centre - Montreal (CAN)

✦ OP 4.5: The IciStem consortium: T-cell immunology in HIV-1 infected individuals after allogeneic stem cell transplantation
Author(s): J. Martinez-Picado 3,*, J. Eberhard 1,*, M. Angin 2, C. Passaes 2, M. Salgado 3, J.L. Díez Martín 4, M. Nijhuis 5, A. Wensing 5, J. Schulze Zur Wiesch 1, A. Sáez-Cirión 2
1Department of Medicine, Infectious Diseases Unit, University Medical Center Hamburg-Eppendorf - Hamburg (GER)
2Institut Pasteur, HIV, Inflammation and Persistence - Paris (FRA)
3AIDS Research Institute IrsiCaixa - Barcelona (SPA)
4Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitarias Gregorio Marañón, Universidad Complutense - Madrid (SPA)
5University Medical Center - Utrecht (NET)

✦ OP 4.6: Dynamics of HIV-Specific T-Cells on Long-Term ART Differ by Antigen Recognized and by Sex
Author(s): Eva M. Stevenson1, Adam R. Ward1,2,3, Thomas R. Dilling1, John K. Bui1, John Mellors4, Rajesh Gandhi5, Deborah McMahon5, Joseph Eron6, Ronald Bosch7, Christina Lala7, Joshua Cykorton, and Brad Jones1,2, for the A5321 Team
1Division of Infectious Diseases, Weill Cornell Medicine, New York, NY (USA)
2Department of Microbiology, Immunology, and Tropical Medicine, George Washington University, Washington, DC (USA)
3PhD program in Epidemiology, George Washington University, Washington, DC (USA)
4University of Pittsburgh, Pittsburgh, PA (USA)
5Massachusetts General Hospital, Boston, MA (USA)
6University of North Carolina, Chapel Hill, NC (USA)
7Harvard University, Boston, MA (USA)
THURSDAY, DECEMBER 12, 2019

SESSION 5: HUMAN STUDIES AND DRUG DEVELOPMENT I

Chairs:
Bonnie HOWELL, Executive Director, Infectious Disease and Vaccines Merck, West Point, Pennsylvania, PE - USA
Javier MARTINEZ PICADO, ICREA Research Professor at Institut de Recerca de la Sida - IrsiCaixa, Barcelona – SPA

- **OP 5.0: Discovery and development of novel latency reversing agents**
  Lecturer: Richard DUNHAM, Scientific Leader and Fellow at ViiV Healthcare; Adj Asst Professor at UNC-CH Région de Raleigh-Durham, NC - USA

- **OP 5.1: Virologic Outcomes of Vesatolimod Administration in People Living with HIV on ART**
  Lecturer: Joseph HESSELGESSER, Research scientist, Gilead, Foster city, CA - USA

- **OP 5.2: HIV Post-Treatment Control Despite Plasma Viral Evolution and Dual Infection**
  Author(s): J. Li 1*, B. Etemad 1, G. Namazi 1, Y. Wen 2, N. Jilg 3, E. Esmaeilzadeh 1, X. Zhang 4, R. Sharaf 1, Z. Brumme 5, M. Kearney 6
  1Brigham and Women’s Hospital, Harvard Medical School - Boston (USA)
  2China Medical University - Shenyang (CHI)
  3Massachusetts General Hospital, Harvard Medical School - Boston (USA)
  4Beijing Friendship Hospital - Beijing (CHI)
  5Simon Fraser University - Burnaby (CAN), 6Frederick National Laboratory for Cancer Research - Frederick (USA)

- **OP 5.3: Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents**
  Author(s): L. Pache 1*, P. Teriete 1, M.D. Marsden 2, A.M. Spivak 3, D. Heinmann 1, A.J. Portillo 1, V, Planelles 3, J.A. Zack 2, N.D.P. Cosford 1, S.K. Chanda 7
  1Sanford Burnham Prebys Medical Discovery Institute - La Jolla (USA)
  2University of California, Los Angeles - Los Angeles (USA)
  3University of Utah School of Medicine - Salt Lake City (USA)

- **OP 5.4: HIV Particles Expressed in Semen under INSTI-based Suppressive Therapy are Largely Myeloid Cell-Derived and Exhibit Widely Diverse Genotypes**
  Author(s): J. Johnson 1*, D. Anderson 2, J.F. Li 1, A. Santos Tino 3, J. Politch 2, J. Lipscomb 1, J. Defelice 4, M. Gelman 4, K. Mayer 4
  1CDC, Atlanta (USA)
  2BU School of Medicine, Boston (USA)
  3The DESA Group, Atlanta, USA
  4The Fenway Institute, Boston (USA)

- **OP 5.5: Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in vivo: The AMC-095 Study**
  Author(s): Thomas A Rasmussen1, Laskhmi Rajdev2, Ajantha Rhodes1, Ashanti Dantanarayana1, Surekha Tennakoon1, Socheata Chea1, Danielle Rigau3, Shelly Lensing4, Rachel Rutishauser5, Sonia Bakkour6, Michael Busch7, Dirk P Dittmer7, Steven Deeks8, Christine Durand9
  1The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Melbourne, (AUS)
  2Department of Medicine, Albert Einstein College of Medicine, New York (USA)
  3Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland (USA)
  4Department of Biostatistics, University of Arkansas for Medical Biosciences, Arkansas (USA)
  5Department of Medicine, University of California San Francisco, California (USA)
  6Vitalant Research Institute, San Francisco, California (USA)
  7Department of Microbiology and Immunology, University of North Carolina (USA)
  8Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne (AUS)

- **OP 5.6: Intact Proviral DNA Levels Decline in People with HIV on Antiretroviral Therapy (ART)**
  Author(s): J. Cyktor 2,*, R. Gandhi 1,*, R. Bosch 1, H. Mar 3, G. Laird 4, B. Macatangay 2, J. Eron 6, R. Siliciano 5, D. Mcmahon2, J. Mellors2
  1Massachusetts General Hospital - Boston (USA),
  2University of Pittsburg - Pittsburgh (USA),
  3Harvard TH Chan School of Public Health - Boston (USA),
  4Accelevir Diagnostics - Baltimore (USA),
  5University of North Carolina - Chapel Hill (USA),

📅 12:30 - 2:00 PM Lunch
SESSION 6: NEW THERAPEUTIC APPROACHES I

Chairs:
Ya-Chi HO, Assistant Professor of Microbial Pathogenesis and Medicine; Investigator, HIV Reservoirs and Viral Eradication Transformative Science Group (Cure TSG) New Haven, CT - USA
Alberto BOSQUE, Assistant Professor, Department of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, WA - USA

- OP 6.0 Genome editing against HIV
Lecturer: Paula CANNON, Professor of Molecular Microbiology & Immunology; Associate Director of Cross School Programs for the MESH Academy Molecular Microbiology and Immunology, Los Angeles, CA - USA

- OP 6.1: Multispecific anti-HIV duoCAR-T cell therapy mediates robust HIV suppression and elimination of HIV-infected cells in humanized mice
Author(s): K. Anthony-Gonda 1,*, A. Bardhi 2, A. Ray 2, W. Krueger 1, D. Schneider 1, Z. Zhu 1, R. Orentas 1, D. Dimitrov 3, H. Goldstein 2, B. Dropulic 1
1Lentigen, a Miltenyi Biotec Company - Gaithersburg (USA)
2Albert Einstein College of Medicine - Bronx (USA)
3University of Pittsburg - Pittsburg (USA)

- OP 6.2: Location, abundance and persistence of CAR/CXCR5 transduced T cells within lymphoid tissues of SIV-infected rhesus macaques
Author(s): H. Abdelaal 1,*, M. Pampusch 1, P. Skinner 1, E. Berger 2
1University of Minnesota - Minneapolis (USA)
2University of Minnesota - The National Institutes of Health, Bethesda, Md (USA)

- OP 6.3: Combinatorial latency reversal activity of Inhibitor of Apoptosis antagonists (IAPa) with mechanistically distinct classes of HIV latency reversal agents
Author(s): S. D. Falcinelli1,3, D. M. Irlbeck1,5, A.-M. Turner1, J. Peterson1,3, F. Potjewyd 2, L. I. James1,2, D. Margolis1,3,4, N. Archin1,4, R. Dunham1,5
1UNC HIV Cure Center (USA)
2Center for Integrative Chemical Biology and Drug Discovery (USA)
3Dept. of Microbiology and Immunology (USA)
4Dept. of Medicine University of North Carolina, Chapel Hill, NC (USA)
5HIV Drug Discovery, ViiV Healthcare, Research Triangle Park, NC (USA)

- OP 6.4: α4α7-blockade delays viral rebound in SHIV infected macaques treated with a combination of HIV bNAbbs
Author(s): E. Martinelli 1,*
CBR, Population Council - New York (USA)

- OP 6.5: Replacing daily cART with AAV-expressed eCD4-Ig
Author(s): M. Gardner 1,*, M. Davis-Gardner 1, M. Farzan 1
1The Scripps Research Institute - Jupiter (USA)

3:30 - 4:00 PM Coffee Break

POSTER VIEWING SESSION WITH WINE AND CHEESE TASTING

DINNER ON YOUR OWN
FRIDAY, DECEMBER 13, 2019

SESSION 7: HUMAN STUDIES AND DRUG DEVELOPMENT II

Chairs:
David SMITH, University of California, San Diego School of Medicine, La Jolla - USA

- **OP 7.0 Main challenges of human studies in the HIV eradication field**
  
  Lecturer: Beatriz MOTHE PUJADAS, MD, PhD. Associate Investigator. HIV Unit & IrsiCaixa AIDS Research Institute. Hospital Germans Trias i Pujol. UVic-UC, Barcelona - SPA

- **OP 7.1: Whole Body Imaging of HIV Persistence, Viral Biomarkers and Immune Activation**
  
  Lecturer: Timothy HENRICH, Associate Professor of Medicine at University of California, San Francisco, CA - USA

- **OP 7.2: Plasma and Antibody Glycomic Biomarkers of Time to HIV Rebound and Viral Setpoint**
  
  Author(s): L. Giron 1,*, E. Papasavvas 1, L. Azzoni 1, K. Mounzer 2, J. Kostman 3, I. Sanne 3, C. Fimhamber 4, Q. Liu 1, L. Montaner 3, M. Abdel-Mohsen 1, 2
  
  1The Wistar Institute - Philadelphia (USA)
  2Philadelphia FIGHT - Philadelphia (USA)
  3University of the Witwatersrand - Johannesburg (ZAF)
  4University of Colorado School of Medicine - Aurora (USA)

- **OP 7.3: Single cell RNA-seq identifies host genes that correlate with HIV-1 reservoir size**
  
  Author(s): R. Thomas 1,*, A. Waickman 2, P. Ehrenberg 1, A. Geretz 1, M. Eller 1, S. Tovanabutra 1, J. Ananworanich 3, N. Chomont 3, J. Currier 3
  
  1U.S. Military HIV Research Program, Walter Reed Army Institute of Research - Silver Spring (USA)
  2Viral Diseases Branch, Walter Reed Army Institute of Research - Silver Spring (USA)
  3Université de Montréal, Faculty of Medicine - Montreal (CAN)

- **OP 7.4: Sex differences in the latent reservoir of virally suppressed HIV-1 infected individuals living in Rakai, Uganda**
  
  Author(s): T.C. Quinn 3,*, J. Prodger 1,*, A.M. Capoferri 2, K. Yu 1, S.J. Reynolds 3, J. Kasule 4, D. Servoadda 2, E. Scully 2, K.J. Kwon 2, A.D. Redd 3
  
  1Western University - London (CAN)
  2Johns Hopkins School of Medicine - Baltimore (USA)
  3National Institutes of Health - Baltimore (USA)
  4Rakai Health Sciences Program - Kalisizo (UGA)

- **OP 7.5: Clones Of HIV Infected Cells Are Widely Distributed In T Cell Subsets In Blood And In Anatomic Tissues**
  
  Author(s): F. Maldarelli 1,*, M. Gozoulis 1, X. Wu 2, L. Perez 3, R. Gorelick 4, C. Lange 1, S. Hill 1, J. Virga 1, T. Uldrick 5, R. Yarchoan 6, S. Hughes 1
  
  1CCR/NCI - Frederick (USA)
  2Leidos Inc - Peoria (USA)
  3VRC/NIAID - Bethesda (USA)
  4Leidos, INC - Peoria (USA)
  5CCR/NCI - U Washington (USA)
  6CCR/NCI - Bethesda (USA)

- **OP 7.6: Tissue-specific differences in the mechanisms that govern HIV latency in blood, liver, gut and genital tract in ART-suppressed women**
  
  Author(s): S. Moron-Lopez 1,*, G. Xie 2, P. Kim 2, J. Wong 3, J. Price 4, N. Elnachef 4, R. Greenblatt 4, P. Tien 1, N. Roan 2, S. Yukl 1
  
  1University of California San Francisco - SFVAMC - San Francisco (USA)
  2University of California San Francisco - Gladstone Institutes - San Francisco (USA)
  3San Francisco VA Medical Center (SFVAMC) - San Francisco (USA)
  4University of California San Francisco - San Francisco (USA)
SESSION 8: NEW THERAPEUTIC APPROACHES II

Chairs:
Susanna VALENTE, Associate Professor Department of Immunology and Microbiology130 Scripps Way, 3C1, Jupiter, FL - USA
Lesley de ARMAS, Department of Immunology and Microbiology, University of Miami Miller School of Medicine, Miami – USA
Guido POLI, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute - ITA

OP 8.0: A viable pathway to HIV-1 remission
Lecturer: Michael FARZAN, Professor and co-chair of the Department of Immunology and Microbiology on the Florida campus of The Scripps Research Institute, FL - USA

OP 8.1: The Human IL-15 Superagonist N803 Does Not Reverse Latency in ART-suppressed, SHIV-infected macaques
Author(s): G. Webb 1, J. Berrocal 2, K. Busman-Sahay 1, S. Abdulhaqq 1, J. Smedley 1, J. Safrit 3, J. Estes 1, P. Skinner 2, J. Sacha 1
1Oregon Health and Science University - Portland (USA)
2University of Minnesota - St. Paul (USA)
3University of Sao Paulo, Infectious Diseases Department - São Paulo (BRA)

OP 8.2: How Long is Long-term? Delivery of anti-HIV Antibodies Using AAV Vector
Author(s): J. Martinez-Navio 1, R. Desrosiers 1, S. Fuchs 1, D. Mendes 1, E. Rakasz 2, G. Gao 3, J. Lifson 4
1University of Miami - Miami (USA)
2Wisconsin National Primate Research Center UW - Madison (USA)
3Gene Therapy Center UMass - Worcester (USA)
4Fred Hutchinson Cancer Research Center - Seattle (USA)

OP 8.3: Intensification of ART with ABX464 decreases the total HIV reservoir and HIV transcription initiation in CD4+ T cells from HIV-infected ART-suppressed individuals
Author(s): S. Bernal 1, S. Moron-Lopez 2, J.M. Steenis 3, J.K. Wong 4, J. Martinez-Picado 1, S.A. Yukl 5
1IrsiCaixa AIDS Research Institute - Badalona (SPA)
2University of California San Francisco - San Francisco (USA)
3ABIVAX - Paris (FRA)
4San Francisco VA Medical Center - San Francisco (USA)

OP 8.4: HIV persistence despite reservoir decay during combinatorial immunotherapy including therapeutic conserved elements (CE) DNA vaccination, PD-1 therapy, GS-986 TLR7-agonism, and CCR5 gene-edited CD4+ T cell infusion in rhesus macaques
Author(s): S. Bernal 1, C. Peterson 2, M. O’Connor 1, H. Tunggal 1, J. Prado 3, B. Varco-Merth 1, H. Park 1, B.K. Felber 2, G.N. Pavlakis 2, J.D. Lifson 3, A.A. Okoye 1
1IrisCaixa - Badalona (Barcelona) (SPA)
2Center for Cancer Research, National Cancer Institute - Frederick, Md (USA)
3The Jenner Institute Nuffield Department of Medicine, University of Oxford - Oxford (GBR),
4Department of Infectious Disease, Merck & Co. Inc. - Kenilworth, Nj (USA)

OP 8.5: PD-1 Blockade boost Vaccine-Induced anti-HIV responses in the absence of HIV reactivation
Author(s): M. Marin Lopez 1, J.-G. Prado, M. Marin Lopez 1, E. Jimenez-Moyano 1, D. Ouchi 1, O. Blanch-Lombarte 1, D. Gorman 2, T. Hanke 3, C. Brander 1, B. Howell 4, B. Mothe 1
1IrsiCaixa - Badalona (Barcelona) (SPA)
2Wistar Institute - Philadelphia (USA)
3Heidelberg University Hospital, Department of Infectious Diseases - Heidelberg (USA)
4Institute of Infectious Diseases, Gemelli Hospital, Catholic University of Sacred Heart - Rome (ITA)
5Federal University of Sao Paulo, Infectious Diseases Department - São Paulo (BRA)
6Department of Infectious Diseases, Italian Institute of Health - Rome (ITA)

OP 8.6: Post-therapy viral set-point abatement following combined antiproliferative and immune-boosting interventions: Results: from a randomized clinical trial
Author(s): R. Sobhie Diaz 1, L.B. Giron 2, J. Galinskas 3, J. Hunter 1, M. Janini 1, I.L. Shytaj 3, R. Cauda 4, M.C. Sucupira 5, A. Savarino 6
1Federal University of Sao Paulo, Infectious Diseases Department - São Paulo (BRA)
2Wistar Institute - Philadelphia (USA)
3Heidelberg University Hospital, Department of Infectious Diseases - Heidelberg (USA)
4Institute of Infectious Diseases, Gemelli Hospital, Catholic University of Sacred Heart - Rome (ITA)
5University of North Carolina, Chapel Hill, NC - USA
6Department of Infectious Diseases, Italian Institute of Health - Rome (ITA)

OP 8.7: B cell depletion alone or in combination with IL-15 or PD-1 blockade facilitates enhanced control of virus replication in SIV-infected rhesus macaques
Author(s): Y. Fukazawa 1, L.J. Picker 1, Y. Fukazawa 1, H. Behms 1, B.E. Randall 1, B. Varco-Merth 1, H. Park 1, B.K. Felber 2, G.N. Pavlakis 2, J.D. Lifson 3, A.A. Okoye 1
1Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University - Beaverton, Or (USA)
2Center for Cancer Research, National Cancer Institute - Frederick, Md (USA)

CLOSING CEREMONY

Alain LAFEUILLADE, Infectious disease private practice, La Valette du Var - FRA
David MARGOLIS, University of North Carolina, Chapel Hill, NC - USA
Karl SALZWEDEL, NIAID, Division of AIDS, Bethesda, MD - USA
Mario STEVENSON, University of Miami Leonard School of Medicine, Miami, FL - USA
SESSION 1: BASIC SCIENCE OF HIV LATENCY

PP 1.1: Remodeling of the core leads HIV-1 pre-integration complex into the nucleus of human lymphocytes
Author(s): F. Di Nunzio 1,*, G. Blanco-Rodriguez 1, A. Gazi 2, B. Monel 3, S. Frabetti 1, V. Scoca 1, O. Schwartz 4, J. Krijnse-Locker 2, P. Charneau 1
1Department of Virology, VMV, Institut Pasteur - Paris (FRA), 2Unit of Ultra-structural bio-imaging (UBI), Institut Pasteur - Paris (FRA), 3Institut Pasteur - Paris (FRA) - 4Department of Virology, UVI, Institut Pasteur - Paris (FRA)

PP 1.2: Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir
Author(s): C. Gaebler 1,*
1The Rockefeller University - New York (USA)

PP 1.3: Single cell analysis reveals molecular signatures of HIV latency in primary cell models
Author(s): S. Telwatte 1,2,*, M. Montano 3, R. Resop 2, E. Battivelli 6, S. Morón-López 1, E. Verdin 5, W. Greene 3, A. Bosque 4, J. Wong 2, S. Yuki 2
1University of California, San Francisco (UCSF) - San Francisco (USA), 2San Francisco VA Health Care System - San Francisco (USA), 3Gladstone Institutes - San Francisco (USA), 4George Washington University - Washington (USA), 5Buck Institute for Research and Aging - San Francisco (USA)

PP 1.4: Evaluation of IAP/SMAC Mimetics as Latency Reversal Agents in Primary Cells and Cytokine induction in In Vivo Models Predictive of Cytokine Release
Author(s): B. Howell 1,*, W. Shipe 1, G. Adam 1, S. Quan 1, L. Li 2, C.N.A. Sim 2, R. Dunham 3, D. Margolis 4, B. Henry 2, D. Hazuda 1
1Merck & Co., Inc - West Point (USA), 2MSD - Singapore (Singapour), 3Viiv - Chapel Hill (USA), 4UNC - Chapel Hill (USA)

PP 1.5: Live-Track of HIV genome in the nuclear space
Author(s): F. Di Nunzio 1,*, V. Scoca 1, G. Blanco-Rodriguez 1, D. Ershov 2, J.Y. Tinevez 2
1Department of Virology, Institut Pasteur - Paris (FRA), 2Image Analysis Hub/ C2RT, Institut Pasteur - Paris (FRA)

PP 1.6: Genome-wide RNAi screen identifies MAPK-RPK required for HIV-1 proviral silencing in non-T cell reservoir cell-line model
Author(s): H. Takeuchi 1,*, T. Ishida 2, Y. Satou 3, J. Gohda 2, H. Kitamura 1, S. Gan 1, K. Takahashi 1, Shoji Yamaoka 2, 1Department of Molecular Virology, Tokyo Medical and Dental University - Tokyo (JAP), 2Research Center for Asian Infectious Diseases, The Institute of Medical Science, The University of Tokyo - Tokyo (JAP), 3Division of Genomics and Transcriptomics, Joint Research Center for Human Retrovirus Infection, Kumamoto University - Kumamoto (JAP)
4Department of Molecular Virology, Tokyo Medical and Dental University, Tokyo, Japan
*authors contributed equally

PP 1.7: Intact HIV Genomes are Enriched in Memory T-cells with Short Half-lives
Author(s): V. Morcilla 1,*, C. Bacchus-Souffan 2, T. Schlub 3, M. Fitch 4, R. Hoh 5, S. Deeks 5, M. Hellerstein 4, J. Mccune 6, P. Hunt 2, S. Palmer 1
1Centre for Virus Research, The Westmead Institute for Medical Research, The University of Sydney - Westmead (Australia), 2Division of Experimental Medicine, Department of Medicine, University of California San Francisco - San Francisco (USA), 3Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney - University of Sydney (Australia), 4Department of Nutritional Sciences and Toxicology, University of California - Berkeley (USA), 5Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, Zuckeberg San Francisco General Hospital, University of California San Francisco - San Francisco (USA), 6Global Health Innovative Technology Solutions/HIV Frontiers, Bill & Melinda Gates Foundation - Seattle (USA)

PP 1.8: HBV-related inflammation is linked to the level of genetically intact HIV proviruses
Author(s): X. Wang 1,2,*, J.M. Zerbato 3, A. Avihingsanon 4, A. Rhodes 5, J. Audsley 5, K. Singh 5, W. Zhao 3, M. Crane 3, P. Hunte 2, S. Palmer 1
1Centre for Virus Research, The Westmead Institute for Medical Research - Westmead (AUS), 2Sydney Medical School, The University of Sydney - Sydney (AUS), 3The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital - Melbourne (AUS), 4HIV-NAT, Thai Red Cross AIDS Research Center (TRCARC) - Bangkok (THA)

PP 1.9: Intact Proviruses from Naive and Effector Memory T-Cells Match Persistent Viremia
Author(s): K. Fisher 1,*, B. Hiener 1, T.E. Schlub 2, E. Lee 1, J.M. Milush 3, R. Hoh 3, R. Fromentin 4, N. Chomont 5, S.G. Deeks 3, S. Palmer 1
1Westmead Institute for Medical Research - Westmead (AUS), 2University of Sydney - Sydney (AUS), 3University of California San Francisco - San Francisco (USA), 4Universite de Montreal - Montreal (CAN)
PP 1.10: Global mapping of the macrophage transcriptome upon CCL2 neutralization reveals an association between activation of innate immune pathways and HIV-1 restriction
Author(s): D.A. Covino 1, L. Fantuzzi 1, J. Lu 2, M.V. Chiantore 3, G. Fiorucci 4, C. Purificato 1, L. Catapano 1, C.M. Galluzzo 1, R. Amici 1, M. Pellegrini 2
1National Center for Global Health, Istituto Superiore di Sanità - Rome (ITA), 2Department of Molecular, Cell, and Developmental Biology, University of California Los Angeles - Los Angeles (USA), 3Department of Infectious Diseases, Istituto Superiore di Sanità - Rome (ITA), 4Institute of Molecular Biology and Pathology, CNR - Rome (ITA)

PP 1.11 - 00078
HIV-1 Replication is Metabolically Regulated in an Ex vivo Human Tonsil Histoculture Model of Infection.
Author(s): R. Furler 1, K. Newcombe 1, D. Nixon 1
1Weill Cornell Medicine - New York (USA)

PP 1.12: Histone deacetylase inhibitors induce transcription of unspliced but not multiply spliced HIV-1 RNA from proviral genomes during latency reversal, affecting antigen presentation and detection by CD8 + T cells
Author(s): T. Mota 1, C. Mccann 1, S.H. Huang 1, M. Dean 1, R. Yanqin 1, R. Thomas 2, K. Colin 3, H. David 4, S. Jeffery 5, J. Brad 6
1Weill Cornell Medicine - Ny (USA), 2GWU - Washington (USA), 3Maple Leaf Clinic - Toronto (CAN), 4Whitman-Walker Health - Washington (USA), 5NantBioScience Inc./NantKwest LLC - Culver City (USA)

PP 1.13: Distinct HIV reservoir measures correlate with defective but not intact pro-viral DNA
Author(s): E. Papasavvas 1, L. Azzoni 1, P. Tebas 2, K. Mounzer 3, J.R. Kostman 4, D. Richman 5, N. Chomont 6, B. Howell 7, L.J. Montaner 1
1The Wistar Institute - Philadelphia (USA), 2University of Pennsylvania - Philadelphia (USA), 3Jonathan Lax Immune Disorders Treatment Center, Philadelphia Field Initiating Group for HIV-1 Trials - Philadelphia (USA), 4John Bell Health Center, Philadelphia Field Initiating Group for HIV-1 Trials - Philadelphia (USA), 5VA San Diego Healthcare System and the University of California - San Diego (USA), 6University of Montreal - Montreal (CAN), 7Merck, Inc. - West Point (USA)

PP 1.14: HIV integration site selection in the 3D genome: impact on viral and host gene expression
Author(s): M. Benkirane 1
1IGH. CNRS-University of Montpellier - Montpellier (FRA)

PP 1.15: Protein crotonylation sensitizes SMACm disruption of latent HIV by modulating the ncNF-κB signaling pathway at the step of p100 cleavage into p52
Author(s): G. Jiang 1, D. Li 1, S. Falcinelli 2, L. Wong 1, C. Garrido 1, C. Galardi 3, R. Dunham 3, E. Brown 1, N. Archin 1, D. Margolis 1
1UNC HIV Cure Center; Institute of Global Health & Infectious Diseases - Chapel Hill (USA), 2UNC HIV Cure Center - Chapel Hill (USA), 3UNC HIV Cure Center; HIV Drug Discovery, ViiV Healthcare - Chapel Hill (USA)

PP 1.16: Interactions with Pathogenic Bacteria Induce HIV-1 Latency in Macrophages through Altered Transcription Factor Recruitment to the LTR
Author(s): T. Hanley 1, V. Planelles 1, G. Viglianti 2
1University of Utah Health - Salt Lake City (USA), 2Boston University School of Medicine - Boston (USA)

PP 1.17: Low-level Persistent/Latent HIV-1 Infection of Macrophages Corresponds to Decreased NF-kB Activity
Author(s): T. Hanley 1, L. Dickey 1, V. Planelles 1
University of Utah Health - Salt Lake City (USA)

PP 1.18: Cell Proliferation Contributes to the Increase of Genetically Intact HIV Over Time
Author(s): S. Palmer 1, B. Horsburgh 1, B. Hiencher 1, K. Fisher 1, E. Lee 1, J. Milush 2, R. Hoh 2, R. Fromentin 3, N. Chomont 2, S. Deeks 2
1Westmead Millennium Institute and University of Sydney - Westmead (AUS), 2Department of Medicine, University of California San Francisco - San Francisco (USA), 3Université de Montréal - Montréal (CAN)

PP 1.19: Intra- and Inter-individual HIV Diversity Limits the Application of the Intact Proviral Detection Assay (IPDA)
Author(s): N. Kinloch1,2, Y. Ren3, W. Conce Alberto3, W. Dong2, S. Han Huang3, A. Wilson4, T. M. Moto3, D. Kikby2, P. M. Del Rio Estrada6, C. J. Brumme2, G. Q. Lee3, R. M. Lynch4, Z. L. Brumme1,2, R. Brad Jones3,4
1Faculty of Health Sciences, Simon Fraser University, Burnaby (CAN), 2BC Centre for Excellence in HIV/AIDS, Vancouver (CAN), 3Division of Infectious Diseases, Weill Cornell Medical College, New York (USA), 4School of Medicine and Health Sciences, George Washington University, Washington DC (USA), 5Department of Investigacion en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City (MEX), 6Faculty of Medicine, University of British Columbia, Vancouver (CAN)
PP 1.20: Exploring histone loading on unintegrated HIV-1 DNA reveals the chromatin dynamics between unintegrated and integrated viral genome. 
Author(s): M. Benkirane 1,*, S. Machida 1,*, D. Depierre 2, M. Takaku 3, O. Cuvier 2
1 Institut de Génétique Humaine, Université de Montpellier. Laboratoire de Virologie Moléculaire CNRS-UMR9002 - Montpellier (FRA), 2 LBME, Centre de Biologie Intégrative (CBI), Université de Toulouse, CNRS - Toulouse (FRA), 3School of Medicine and Health Sciences, University of North Dakota - North Dakota (USA)

PP 1.21: A novel, ultra-sensitive technology for quantifying the HIV unintegrated linear DNA responsible for pre-integrative latency.
Author(s): J. Dutrieux 9,*, H. Roux 1,2,*, J. Migraine 3, M. Salmona 4, J. Hamroune 2, N. Arhel 6, A. Hance 7, F. Clavel 4, R. Cheynier 2
1 Université de Paris - Paris (FRA), 2 Institut Cochin, INSERM, U1016, CNRS, UMR8104 - Paris (FRA), 3Inserm U1259 - Tours (FRA), 4 Université de Paris, Assistance Publique Hôpitaux de Paris, Hôpital Saint Louis - Paris (France), 5 Institut de Recherche en Infectiologie de Montpellier, CNRS UMR 9004 - Montpellier (FRA), 7 Assistance Publique Hôpitaux de Paris, Hôpital Saint Louis - Paris (FRA), 9 Inserm U949 - Paris (FRA)

PP 1.22: A novel, ultra-sensitive technology for quantifying the HIV unintegrated linear DNA responsible for pre-integrative latency.
Author(s): J. Dutrieux 6,*, H. Roux 1,2,*, J. Migraine 3, M. Salmona 4, J. Hamroune 2, N. Arhel 5, A. Hance 6, F. Clavel 4, R. Cheynier 2
1 Université de Paris - Paris (FRA), 2 Institut Cochin, INSERM, U1016, CNRS, UMR8104 - Paris (FRA), 3Inserm U1259 - Tours (FRA), 4 Université de Paris, Assistance Publique Hôpitaux de Paris, Hôpital Saint Louis - Paris (France), 5 Institut de Recherche en Infectiologie de Montpellier, CNRS UMR 9004 - Montpellier (FRA), 6INSERM U941 - Paris (FRA)

PP 1.23: A delicate balance between the number of RBEIII and NF-κB motifs impacts latency kinetics in HIV-1
Author(s): U. Ranga 1,*, D. Bhange 1, N. Prasad 1
Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) - Bangalore (IND)

PP 1.24: Epigenomic characterization of a primary cell model of HIV latency.
Author(s): E. Browne 1,*, B. Pace 1, D. Margolis 1, B. Strahl 1, R. Dromaramu 1, S. Jefferys 1, J. Parker 1
UNC-Chapel Hill - Chapel Hill (USA)

PP 1.25: Proteasomal degradation of PML protein is a stress response to HIV-1 replication and reactivation
Author(s): I. Shytaj 1,2,*, B. Lucic 1, C. Penzo 1, S. Bicciato 3, M. Forcato 3, A. Savarino 4, M. Lusic 1
1 Department of Infectious Diseases, Integrative Virology, Heidelberg University - Heidelberg (GER), 2 German Center for Infection Research (DZIF) - Heidelberg (GER), 3 Department of Life Sciences, University of Modena and Reggio Emilia - Modena (ITA) - 4 Department of Infectious and Immune-Mediated Diseases, Italian Institute of Health - Rome (ITA)

PP 1.26: Expression of CircRNAs in HIV-1 latently infected cells from an in vitro model
Author(s): L. Iniguez 1,*, D.C. Copertino Jr 1, D.F. Nixon 1, M. De Mulder Rougvie 1
Weill Cornell Medicine - New York (USA)

PP 1.27: Cleavage And Polyadenylation Specific Factor 6 is required for HIV latency reversal
Author(s): Y. Zheng 1,*, A. Nau 2, V. Achuthan 3, A. Engelman 3, V. Planelles 1
1 Department of Pathology, School of Medicine, University of Utah - Salt Lake City (USA), 2 Department of Biochemistry, School of Medicine, University of Utah - Salt Lake City (USA), 3 Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School - Boston (USA)

PP 1.28: Using Single-cell Analysis and a Primary Model of HIV to study Latency Establishment and Reactivation
Author(s): L. De Armas 1,*, S. Williams 1, L. Pan 1, S. Rinaldi 1, S. Pallikkuth 1, R. Pahwa 1, S. Pahwa 1
University of Miami Miller School of Medicine - Miami (USA)

PP 1.29: Degradation of the XBP subunit of TFIIH by Spironolactone reduces HIV-1 reactivation from latency
Author(s): L. Mori 1,*, Y.C. Ho 2, B.C. Ramirez 3, S. Valente 1
1 The Scripps Research Institute, Department of Immunology and Microbiology - Jupiter (USA), 2 Department of Microbial Pathogenesis, Yale University School of Medicine - New Haven (USA), 3 Institut Cochin, Inserm, CNRS, Université Sorbonne Paris Cité - Paris (FRA)

PP 1.30: Updates on Two Public Databases for Studies of HIV Persistence; the Retrovirus Integration Database (RID) and HIV Proviral Sequence Database (PSD)
Author(s): W. Shao 1,*, J. Shan 1, W.S. Hu 2, E. Halvas 3, J. Mellors 3, J. Coffin 4, M. Kearney 2
1 Leidos Biomedical Research, INC - Frederick (USA), 2 HIV Dynamics and Replication Program, NCI - Frederick (USA), 3 Division of Infectious Disease, University of Pittsburgh - Pittsburgh (USA), 4 Tufts University - Boston (USA)
PP 1.31: Specificity of Bivalent Chemical Degraders Targeted to the BET Proteins
Author(s): A-M. Turner 1,*, F. Potjewyd 2, A. Keller 3, L. James 2, D. Margolis 1
1UNC HIV Cure Center, Departments of Medicine and Microbiology/Immunology, UNC Chapel Hill School of Medicine, University of North Carolina Chapel Hill (USA), 2Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina Chapel Hill - Chapel Hill (USA), 3UNC HIV Cure Center, University of North Carolina Chapel Hill - Chapel Hill (USA)

PP 1.32: Utilizing Genetic Barcodes to Understand the Role of Silent Integration in HIV Latency
Author(s): E. Larragoite 1,*, K.E. Kimball 1, E. Atindaana 2, A. Telesnitsky 2, V. Planelles 1
1University of Utah School of Medicine, Department of Pathology - Salt Lake City (USA), 2University of MichiganSalt Lake City Medical School, Microbiology and Immunology - Ann Arbor (USA)

PP 1.33: Factors Associated with Viral Control after Structured Treatment Interruptions
Author(s): N. Jilg 1,*, B. Etemad 2, R. Dele-Oni 2, C. Wong 2, E. Aga 3, R. Bosch 3, D. Kuritzkes 4, I. Frank 4, J. Jacobson 5, J. Li 5
1Massachusetts General Hospital - Boston (USA), 2Brigham and Women’s Hospital - Boston (USA), 3Harvard T. H. Chan School of Public Health - Boston (USA), 4Pereleman School of Medicine - Philadelphia (USA), 5Case Western Reserve University - Cleveland (USA)

PP 1.34: Visualization of HIV Reactivation from Latency in Primary Resting Memory T-cells
Author(s): F. Kizito 1,*, J. Karn 1,*, U. Mbonye 1, C. Dobrowolski 1, S. Valadkhan 1
Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine - Cleveland (USA)

PP 1.35: An Unbiased Platform to Identify Regulators of HIV Latency in Infected Primary Human CD4+ T Cells
Author(s): U. Rathore 1,2,*, J. Hiatt 1, D.A. Caverio 1, A. Marson 1,*
1Department of Microbiology and Immunology, University of California, San Francisco - San Francisco (USA), 2Diabetes Center, University of California, San Francisco - San Francisco (USA)

PP 1.36: HIV-1 genomes cluster in nuclear niches of human macrophages
F. Di Nunzio 1,*, Francesca Di Nunzio1, Elena Rensen1,2, Florian Mueller2, Viviana Scoca1, Jyotsana Parmar2, Phillippe Souque1, Christophe Zimmer2,
1Virologie Moléculaire et Vaccinologie, Department of Virology, Pasteur Institute, Paris, France 2Imagerie et Modélisation, Département Biologie Cellulaire et Infections, UIM, C3BI, Pasteur Institute, Paris, France
SESSION 2: IN VITRO AND ANIMAL MODELS STUDIES OF HIV PERSISTENCE

PP 2.1: Elimination of HIV-1/SHIV infected cells by combinations of bispecific HIV x CD3 DART® molecules
Author(s): M. Tuyishime 1,*, J. Pickeral 1, N. Jeffrey 1, C. Ann 1, S. Guido 1, M. David 1, F. Guido 1
1Department of Surgery, Duke University Medical Center - Durham (USA), 2MacroGenics - Rockville (USA),
3Yerkes National Primate Research Center, Emory University - Atlanta (USA), 4Department of Pediatrics,
Emory University - Atlanta (USA), 5UNC HIV Cure Center, Departments of Medicine, Microbiology and
Immunology, and Epidemiology, University of North Carolina at Chapel Hill - Chapel Hill (USA)

PP 2.2: Subtype and tropism can influence the establishment and inducibility of latent HIV-1 in primary CD4 T cells
Author(s): I. Sarabia 1,*, S.H. Huang 2, A.R. Ward 2, R.B. Jones 2, A. Bosque 1
1George Washington University - Washington (USA), 2Weill Cornell Medicine - New York (USA)

PP 2.3: Biomarkers to predict reactivation from latency in SIV infection
Author(s): M. Pinkevych 1,*, M. Davenport 1,*, C. Fennessey 2, C. Trubey 2, K. Brandon 2
1UNSW Sydney - Sydney (Australia), 2Frederick National Laboratory for Cancer Research - Frederick (USA)

PP 2.4: The Effect of Natural Killer Cells on Viral Rebound in HIV-1-infected Humanized Mice
Author(s): J. Kim 1,*, C. Camonna 1, K. Farell 1, T.H. Zhang 1, H. Chen 1, M. Dimpasoc 1, M. Soliman 1, M. Marsden 1, R. Sun 1, J. Zack 1
University of California Los Angeles - Los Angeles (USA)

PP 2.5: Cell-associated provirus size decreases in the xenografted CD4+T cells from chronically infected
natural host in a novel simianized mice model
Author(s): Z. Yuan 1,*, S. Lai 2, K. Portion 2, R. Fast 3, I. Ourmanov 2, A. Buckler-White 2, J. Lifson 3, J. Brenchley 3,
L. Montaner 1, V. Hirsch 2
1Wistar Institute - Philadelphia (USA), 2NIH - Bethesda (USA), 3NCI - Frederick (USA)

PP 2.6: µ-Lat: A High-Throughput Humanized Mouse Model of Latent HIV Infection
Author(s): H. Sperber 1,*, P.P. Togarrati 1, K. Raymond 1, M.S. Bouzidi 1, R. Giffinova 1, M.O. Muench 1, S.K. Pillai 1
Vitalant Research Institute - San Francisco (USA)

PP 2.7: Donor T cell chimerism correlates with viral reservoir clearance following allogeneic stem cell
transplantation in fully CART-suppressed Mauritian cynomolgus macaques
Author(s): H. L. Wu 1, W. Weber 1, S. A. Abdulhaqq 1, C. Shriver-Munsch 2, T. Swanson 2, M. Northrup 1,*,
K. Armantrout 2, H. Price 2, M. Robertson-LeVay 2, J. S. Reed 1, K. B. Bateman 1, B. N. Bimber 2, S. L. Junell 2,
Rhonda MacAllister 2, A. W. Legasse 2, M. K. Axthelm 2, C. Moats 2, J. Smedley 2, T. R. Hobbs 2,
L. D. Martin 2, G. Meyers 3, R. T. Maziarz 2, B. J. Burwitz 2, J. Stanton 2, J. B. Sacha 2
1Vaccine and Gene Therapy Institute, 2Oregon National Primate Research Center, 3Center for Hematologic
Malignancies, Knight Cancer Institute, 4Division of Medical Physics, Department of Radiation Medicine,
Oregon Health and Science University, Portland, Oregon (USA)

PP 2.8: Unprimed CD8+ lymphocytes promote the establishment of HIV latency in CD4+ T cells
Author(s): L. Franchitti 1,*, Z. Zhang 2, J. Yoon 2, M. Paiardini 1, G. Silvestri 1, D.A. Kulpa 1, 2
1Yerkes National Primate Research Center, Department of Pathology & Laboratory Medicine, and Emory
Vaccine Center - Atlanta (USA), 2Department of Pediatrics, Emory University School of Medicine - Atlanta (USA)

PP 2.9: Origin of Rebound Virus in Chronically SIV-Infected Monkeys Following Treatment Discontinuation
Author(s): D. Barouch 1,*, P-T. Liu 1,*, B. Keele 2, P. Abbink 1, N. Mercado 1, R. Geleziunas 3
1Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School -
Boston (USA), 2AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research -
Frederick (USA), 3Gilead Sciences - Foster City (USA)

PP 2.10: Barcoded HIV reveals effects of PKC modulation on viral reservoir
Author(s): J. Zack 1,*, M. Marsden 1,*, T.H. Zhang 1, Y. Du 1, M. Dimpasoc 1, X. Wu 1, P. Wender 2, R. Sun 1
1UCLA - Los Angeles (USA), 2Gilead Sciences - Foster City (USA)

PP 2.11: IL-17A Imprints Intestinal Epithelial Cells with the Ability to Promote HIV-1 Dissemination/
Outgrowth in CD4+ T-Cells
Author(s): T. Wiche Salinas 1,*, A. Gosselin 2, B. Mariana 3, H. Touil 1, Y. Zhang 2, J.P. Routy 4, É.A. Cohen 3,
C.L. Tremblay 1, P. Ancuta 1
1UNIVERSITY OF MONTREAL - Montréal (CAN), 2CRCHUM - Montréal (CAN), 3IRCM - Montréal (CAN),
4McGill University - Montréal (CAN)
POSTER PRESENTATION

- **PP 2.12**: Evaluating latency reactivation synergies between the bromodomain inhibitor iBET-151 and the SMAC mimetic AZD5582 in SIV-infected macaques on ART
  Author(s): A.A. Okoye 1,*, Y. Fukazawa 1,*, B.E. Randall 1, R. Lum 1, B. Varco-Merth 1, S.D. Falcinelli 2, J. Medley 1, R. Dunham 2, J.D. Lifson 3, L.J. Picker 1
  1Vaccine & Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University - Beaverton, Or (USA), 2UNC HIV Cure Center, University of North Carolina at Chapel Hill and HIV Drug Discovery, ViiV Healthcare - Research Triangle Park, Nc (USA), 3AIDS and Cancer Virus Program, Frederick National Laboratory - Frederick, Md (USA)

- **PP 2.13**: Next Generation Sequencing in a direct infection model reveals important parallels to in vivo reservoir dynamics
  Author(s): U. O'Doherty 1,*, M. Pinzone 1,*, M.P. Bertuccio 2, D.J. Vanbelzen 3
  1University of Pennsylvania - Philadelphia (USA), 2University of Messina - Messina (Italie), 3Northwestern University - Evanston (USA)

- **PP 2.14**: Treatment of SHIV-infected, ART-suppressed rhesus macaques with bispecific HIVxCD3 DART® molecules
  Author(s): D. M. Gorman 1, M.-T. Lai 2, C. McHale 2, M. Lu 2, D. Graham 2, J. Strizki 2, Y. Zheng 1, S. Ma 1, S. Moltagh 1, M. Bailly 1, S. Hseih 1, G. Azad 1, Yaoli Song 1, F. Ugarte 1, R. Rieder 1, W. Blumenschein 1, D. Hazuda 2, J. Nordstrom 3, B. Howell 2
  1Merck - South San Francisco CA (USA), 2Merck - West Point PA (USA), 3Macrogenics - Rockville MD (USA)

- **PP 2.15**: Single-cell transcriptome of in vivo SIV-infected rhesus macaque CD4 T cells
  Author(s): A. Tokarev 1,2,*, A. Geretz 1, P. Ehrenberg 2, M. Roederer 3, R. Thomas 1, D.L. Bolton 1
  1The Henry Jackson Foundation for the Advancement of Military Medicine - Bethesda (USA), 2US Military HIV Research Program - Silver Spring (USA), 3Vaccine Research Center, NIAID, NIH - Bethesda (USA)

- **PP 2.16**: Novel SHIVs encoding transmitted/founder Envs for latency and cure research
  Author(s): A. Bauer 1,*, E. Lindemuth 1, L. Kuri-Cervantes 1, H. Li 1, M. Watkins 2, W. Ziani 2, H. Xu 2, R. Veazey 2, G. Shaw 1, K. Bar 1
  1University of Pennsylvania - Philadelphia (USA), 2TNPRC - Covington (USA)
SESSION 3: VIROLOGY OF HIV PERSISTENCE

PP 3.1: Automated high-throughput quantification of persistent HIV-1 plasma viremia in individuals on ART
Author(s): J. Jacobs 1,*, M. Tosiano 1, D. Koontz 1, A. Worlock 2, K. Harrington 2, K. Shutt 1, S. Bakkour 3, M. Busch 4, J. Mellors 1
1University of Pittsburgh School of Medicine, Department of Medicine, Division of Infectious Diseases - Pittsburgh (USA), 2Hologic, Inc. - San Diego (USA), 3Vitalant Research Institute - San Francisco (USA)

PP 3.2: Proviral Landscape In Children Parallels Adults And Enables Reservoir Reconstruction
Author(s): J. Hasson 1,*, M.G. Katusiime 2, S. Smith 3, M. Cotton 2, E. Boritz 3, J. Coffin 4, J. Mellors 5, S. Patro 1, G. Van Zyl 2, M. Kearney 1
1National Cancer Institute - Frederick (USA), 2Stellenbosch University - Cape Town (ZAF), 3National Institute of Allergy and Infectious Diseases - Bethesda (USA), 4Tufts University - Boston (USA), 5University of Pittsburgh - Pittsburgh (USA)

PP 3.3: The dynamics of HIV-1 quasispecies diversity circulating in the plasma RNA and cellular DNA of patients with ART
Author(s): M. Liying 3,*, Z. Yuanyuan 1,*, Y. Qianqian 1, N. Ming 2, L. Tingting 3, W. Chen 1, D. Yibo 1, L. Lingjie 1, X. Hui 1, C. Chen 3
1State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention - Beijing (CHI), 2Beijing Institute of Radiation Medicine - Beijing (CHI), 3Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University - Beijing (CHI)

PP 3.4: High-Throughput Sequencing of Integrated HIV-1 Reveals Novel Proviral Structures
Author(s): K. Joseph 1,*, E. Halvas 1, L. Brandt 1, S. Patro 2, J. Rausch 3, M. Kearney 2, J. Coffin 4, J. Mellors 1
1University of Pittsburgh, Department of Medicine, Division of Infectious Disease - Pittsburgh, Pa (USA), 2HIV Dynamics and Replication Program, National Cancer Institute - Frederick, Md (USA), 3Basic Research Laboratory, Center for Cancer Research, National Cancer Institute - Frederick, Md (USA), 4Tufts University - Boston, Ma (USA)

PP 3.5: nHIV-Infected Cells that Survive Co-culture with HIV-specific CTL Exhibit Distinctive Viral Messenger RNA Transcript Profiles
Author(s): R.B. Jones 1,*, G. Lee 1,*, T. Klevorn 1, Y. Ren 1
Weill Cornell Medical College - New York (USA)

PP 3.6: HIV Proviruses with Identical Sequences Arise from Cell Expansion and Infection by a Common Ancestor Virus
Author(s): S. Patro 1,*, A. Niyongabo 1, S. Guo 2, X. Wu 2, E. Boritz 3, S. Deeks 4, F. Maldarelli 1, S. Hughes 1, J. Coffin 5, M. Kearney 1
1HIV Dynamics and Replication Program, National Cancer Institute - Frederick (USA), 2Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research - Frederick (USA), 3Virus Persistence and Dynamic Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases - Bethesda (USA), 4Department of Medicine, University of California San Francisco - San Francisco (USA), 5Department of Molecular Biology and Microbiology, Tufts University - Boston (USA)

PP 3.7: Diversity of the replication-competent HIV reservoir in treated patients
Author(s): A. Nicolas 1,2,*, J. Migraine 1, J. Dutrieux 1, M. Salmona 1,3, A. Tazuin 4, A. Hachiya 5, J.M. Molina 3, F. Clavel 3, A. Hance 1, F. Mammano 4.
1Inserm U941 - Paris (FRA), 2Inserm U1124 - Paris (FRA), 3APHP, Hôpital Saint-Louis - Paris (FRA), 4Inserm U941, Inserm U1124 - Paris (FRA), 5National Hospital Organization Nagoya Medical Center - Nagoya (JAP)

PP 3.8: Peripheral blood SIV/HIV originates from infected cells in tissues
Author(s): M. Betts 1, L. Kuri Cervantes 1, M.B. Pampena 1, S. Samer 2, D. Khoury 3, I. Frank 1, M. Paiardini 2, M. Davenport 3, K. Bar 1, R. Veazey 4
1University of Pennsylvania - Philadelphia (USA), 2Emory University - Atlanta (USA), 3The Kirby Institute - Sydney (AUS), 4Tulane National Primate Research Center - Convincing (USA)

PP 3.9: Ultradeep Analysis of Pretherapy HIV Predicts Large and Genetically Complex Reservoirs During Antiretroviral Therapy
Author(s): K. Huik 1,*, J. Hattori 1, V. Boltz 1, J. Rausch 1, W. Shao 2, M. Kearney 1, J. Coffin 3, F. Maldarelli 1
1HIV Dynamics and Replication Program, NCI, NIH - Frederick (USA), 2Leidos Biomedical Research - Frederick (USA), 3Tufts University - Boston (USA)
POSTER PRESENTATION

PP 3.10: In Vivo Analysis of HIV From an Occupational Exposure to Laboratory Adapted HIV-IIIB With Twenty Year Follow-Up: Implications for Reservoir Formation
Author(s): C. Lange 1,*, N. Lindo 2, R. Little 2, T. Uldrick 3, S. Hill 1, J. Bell 2, K. Lurain 2, R. Ramaswami 2, R. Yarchoan 2, F. Maldarelli 2
1National Cancer Institute - Frederick (USA), 2National Cancer Institute - Bethesda (USA), 3Fred Hutch Cancer Research Center - Seattle (USA)

PP 3.11: Post-ATI viremia in a hyperacute subject comprises macrophage-tropic viral variants
Author(s): V. Machado 1,*, M. Sharkey 1, T. Cordeiro 1, L. Barrios 1, T. Henrich 2, M. Stevenson 1
1University of Miami - Miami (USA), 2University of California San Francisco - San Francisco (USA)

PP 3.12: Long-term persistence of HIV-infected cell clones in early treated children
Author(s): M. Bale 1,*, M.G. Katusiime 2, D. Wells 3, X. Wu 3, J. Coffin 4, M. Cotton 6, S. Hughes 1, J. Mellors 6, G. Van Zyl 2, M. Kearney 2
1HIV Dynamics and Replication Program, CCR, National Cancer Institute - Frederick (USA), 2Division of Medical Virology, Stellenbosch University - Cape Town (ZAF), 3Leidos Biomedical Research Inc. - Frederick (USA), 4Department of Molecular Biology and Microbiology, Tufts University - Boston (USA), 5Department of Pediatrics and Child Health, Tygerberg Children’s Hospital and Family Clinical Research Unit - Cape Town (ZAF), 6Department of Medicine, University of Pittsburgh - Pittsburgh (USA)

PP 3.13: CXCR4-usage HIV-1 strains isolated from blood and cerebrospinal fluid in subjects on suppressive antiretroviral therapy
Author(s): A. Nath 1,*, G. Li 1,*, L. Henderson 1, B. Smith 1, L. Reoma 1, X. Jiao 2, U. Santamaria 1, H. Imamichi 2, C. Lane 3
1NIH/NINDS - Bethesda (USA), 2NIH/NIAID - Frederick (USA), 3NIH/NIAID - Bethesda (USA)

PP 3.14: Marked variation in the susceptibility of HIV-1 to type 1 interferon inhibition during early, late and rebound infection
Author(s): M. Gondim 1,*, S. Sherrill-Mix 1, M. Saag 2, M. Nussenzweig 3, J. Silicano 4, P. Sharp 5, P. Borrow 6, L. Montaner 7, K. Bar 1, B. Hahn 1,*
1Department of Medicine, University of Pennsylvania - Philadelphia (USA), 2Department of Medicine, University of Alabama at Birmingham - Birmingham (USA), 3Laboratory of Molecular Immunology, The Rockefeller University - New York (USA), 4Department of Medicine, Johns Hopkins University - Baltimore (USA), 5Institute of Evolutionary Biology, University of Edinburgh - Edinburgh (GBR), 6Nuffield Department of Clinical Medicine, University of Oxford - Oxford (United Kingdom), 7Vaccine and Immunotherapy Center, The Wistar Institute - Philadelphia (USA)

PP 3.15: Single-cell multiplexed RNA flow-FISH analysis of primary human samples reveals distinct VR reactivation profiles among LRA classes and curtailed VR transcriptional and translational reactivation patterns by HDAC inhibitors
Author(s): D. Kaufmann 1,*, G. Sannier 1,*, M. Dubé 1, N. Brassard 1, G.G. Delgado 1, A. Baxter 1, J.P. Routy 2, N. Chomont 1
1Research Centre of the Centre Hospitalier de l’Université de Montréal (CRCHUM), Université de Montréal - Montreal (CAN), 2Chronic Viral Illnesses Service and Division of Hematology, McGill University Health Centre - Montreal (CAN)

PP 3.16: HIV-1 sequence compartmentalization and evolution in CNS and immune tissue
Author(s): M. Gonzalez-Perez 1,*, R. Rose 2, D.J. Nolan 2, S.L. Lamers 2, P.R. Clapham 1, K. Luzuriaga 1
1University of Massachusetts Medical School - Worcester (USA), 2BioInfoExperts LLC - Thibodaux (USA)

PP 3.17: Intact and replication-competent reservoir virus populations differ from each other and rebound plasma viruses
Author(s): K. Bar 1,*, F. Mampe 1, M.A. Monroy 1, E. Lindemuth 1, L. Kuri Cervantes 1, F. Bibollet-Ruche 1, B. Hahn 1, D.B. Salantes 1
University of Pennsylvania - Philadelphia (USA)

PP 3.18: Longitudinal Sequencing Reveals Multiphasic Decay of HIV Reservoir
Author(s): L. Cannon 1,*, M. Pinzone 1, E. Venanzi-Rullo 1, U. O’doherity 1
University of Pennsylvania - Philadelphia (USA)
SESSION 4: IMMUNOLOGY OF HIV PERSISTENCE

PP 4.1: Baseline inducible HIV P24 is associated with viral control during interferon-κ monotherapy with ART interruption
Author(s): L.J. Montaner 1,*, L. Azzoni 1,*, E. Papasavvas 1, P. Tebas 2, K. Mounzer 3, B. Howell 4, D. Holder 5, N. Chomont 6, L. Kuri Cervantes 2, M. Betts 2
1The Wistar Institute - Philadelphia (USA), 2University of PA - Philadelphia (USA), 3Philadelphia FIGHT - Philadelphia (USA), 4Merck, inc. - West Point (USA), 5Merck, Inc. - West Point (USA), 6Université de Montréal - Montreal (CAN)

PP 4.2: Enhancement of antiviral CD8+ T-cell responses and complete remission of metastatic melanoma in an HIV-1 infected subject treated with pembrolizumab
Author(s): O. Blanch-Lombarte 1,*, C. Gálvez 1, B. Revollo 2, E. Jiménez-Moyano 1, J. M Llibre 2, J. Dalmau 1, D. E. Speiser 3, B. Clotet 2, J. G Prado 1, J. Martinez-Picado 1
1AIDS Research Institute, IrsiCaixa - Badalona (SPA), 2Infectious Diseases Department, University Hospital “Germans Trias i Pujol” - Badalona (SPA), 3Department of Oncology, University of Lausanne - Lausanne (CHE)

PP 4.3: Characterizing antibody responses in ART-treated individuals
Author(s): A. Wilson 1,*, Y. Ren 2, E. Stevenson 2, R.B. Jones 2, R. Lynch 1
1George Washington University - Washington (USA), 2Weill Cornell School of Medicine - New York (USA)

PP 4.4: Th2 cytokines are associated with higher levels of intact proviruses on ART
Author(s): J. Cyktor 1,*, H. Mar 2, G. Laird 3, R. Bosch 2, A. Martin 3, J. Eron 4, B. Macatangay 1, D. Mcmahon 1, R. Gandhi 1, J. Mellors 1
1University of Pittsburgh - Pittsburgh (USA), 2Harvard University - Boston (USA), 3Accelevir Diagnostics - Baltimore (USA), 4University of North Carolina - Chapel Hill (USA), 5Massachusetts General Hospital - Boston (USA)

PP 4.5: Marker of gut damage REG3β and microbial translocation are associated with integrated HIV DNA in CD4 T-cells during early HIV infection
Author(s): S. Isnard 1,*, F.P. Dupuy 1, J. Lin 1, B. Fombuena 1, R. Ramendra 1, J. Ouyang 1, B. Lebouché 1, C. Costiniuk 1, C. Tremblay 2, J.P. Routy 1
1McGill University - Montréal (CAN), 2Université de Montréal - Montréal (CAN)

PP 4.6: BCL-2 Antagonism Sensitizes CTL-Resistant HIV Reservoirs to Elimination Ex Vivo
Author(s): R.B. Jones 1,3,4, Y. Ren 1, S.H. Huang 1, S. Patel 2, W.C. Alberto 1, D. Magat 1, D. Ahimovic 1, A.B. Macedo 3, A. Bosqué 3, C.M. Bollard 2
1Infectious Diseases Division, Weill Cornell Medicine - New York, Ny (USA), 2Childrens National Medical Center - Washington, Dc (USA), 3Dept of Microbiology, Immunology, and Tropical Medicine, The George Washington University - Washinton, Dc (USA)

PP 4.7: PD-1+ CD4 T cells are associated with HIV reservoir size and impaired function of T follicular helper cells in children and young adults on long-term viral control
Author(s): S. Rinaldi 1,*, V. Dinh 1, S. Palilikkuh 1, L. De Armas 1, R. Pahwa 1, N. Cotugno 2, E. Nastouli 3, C. Foster 4, P. Palma 2, S. Pahwa 1
1Department of Microbiology and Immunology, University of Miami Miller School of Medicine - Miami (USA), 2Bambino Gesu Children’s Hospital - Rome (ITA), 3UCL Great Ormond Street Institute of Child Health - London (United Kingdom), 4Imperial College Healthcare NHS Trust - London (GBR)

PP 4.8: Restriction Factor Expression in HIV-1 Vertically Infected Children
Author(s): D. Copertino Jr 1,*, M. Bortlik 2, B. Phillip 2, G. Beckerle 1, C. Ormsby 3, M. Rosenberg 4, R.A.S. Raposo 2, D. Nixon 1, M. De Mulder Rougvie 1
1Weill Cornell Medicine - New York (USA), 2Department of Microbiology, Immunology and Tropical Medicine, The George Washington University - Washington (USA), 3Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases - Mexico City (MEX), 4Pediatric Infectious Diseases Department, Jacobi Medical Center - Bronx (USA)

PP 4.9: HIV-infected macrophages evade NK cell-mediated killing while driving inflammation
Author(s): K. Clayton 1,*, H. Stuart 1, G. Mylvaganam 1, A. Villasmil Ocando 1, M. Maus 2, B. Walker 1
1Ragon Institute of MGH, MIT and Harvard - Cambridge (USA), 2Massachusetts General Hospital - Cambridge (USA)

PP 4.10: A Modified TZM-bl Assay (MoCo-TZA) Documents Replication-Competent HIV in Circulating Monocytes Despite 2 years of Antiretroviral Therapy Initiated Early During Acute Infection
Author(s): B. Mitchell 1,*, E. Laws 1, R. Paul 2, S. Vasan 3, E. Kroon 3, V. Valcour 4, S. Spudich 5, C. Shikuma 1, J. Ananworanich 3, L. Ndhlovu 1
1University of Hawaii - Honolulu (USA), 2Missouri Institute of Mental Health - St. Louis (USA), 3South East Research Collaboration in HIV - Bangkok (THA), 4Memory and Aging Center - San Francisco (USA), 5Yale University - New Haven (USA)
**PP 4.11: B Cells Mediate R5-Tropic HIV Infection of CCR5neg Naive CD4+ T Cells**

Author(s): A. Gerberick ¹,*, N. Sluis-Cremer ¹, P. Piazza ¹, D. Delucia ¹, C. Rinaldo ¹, G. Rappocciolo ¹
University of Pittsburgh - Pittsburgh (USA)

**PP 4.12: Harnessing the specialized effector function of FcRί− NK cells to control HIV-1 infection**

Author(s): R. Anderko ¹,*, C. Rinaldo ¹, R. Mailliard ¹
University of Pittsburgh - Pittsburgh (USA)
PP 5.7.1: From Reservoirs to the Real World: A Framework for Integrating Behavioral and Social Sciences Research into Biomedical HIV Cure-Related Research
Author(s): K. Dube 1,*, J.D. Auerbach 2, M.J. Stirratt 3, P. Gaist 4
1UNC Gillings School of Global Public Health - Chapel Hill, (USA), 2School of Medicine, University of California San Francisco - San Francisco (USA), 3Division of AIDS Research (DAR), National Institute of Mental Health (NIMH), National Institutes of Health (NIH) - Bethesda (USA), 4Office of AIDS Research, Division of Program Coordination, Planning, and Strategic Initiatives, Office of the Director, NIH - Bethesda (USA)

PP 5.7.2: Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure
Author(s): C. Gálvez 1,*, C. Casado 2, M. Pernas 2, L. Tarancón-Diez 3, C. Rodríguez 4, R. Lorenzo-Redondo 5, E. Ruiz-Mateos 5, M. Salgado 1, C. Lopez-Galindez 2, J. Martinez-Picado 1
1AIDS Research Institute IrsiCaixa - Badalona (SPA), 2Centro Nacional de Microbiología. Instituto de Salud Carlos III - Madrid (SPA), 3Institute of Biomedicine of Seville (IBiS) - Seville (SPA), 4Centro Sanitario Sandoval - Madrid (SPA), 5Northwestern University Feinberg School of Medicine - Chicago (USA)

PP 5.7.3: Awareness of HIV cure-directed research among HIV clinic patients in Philadelphia
Author(s): L.J. Montaner 1,*, B. Peterson 1, C. White 2, W. Freshwater 2, M. Lefae 3, C. Roebuck 4, N. Jones 5, D. Robinson 6, S. Johnson 6
1The Wistar Institute - Philadelphia (USA), 2BEAT-HIV CAB - Philadelphia (USA), 3AIDS Law Project - Philadelphia (USA), 4Cornell University - Ithaca (USA), 5Temple University - Philadelphia (USA), 6Philadelphia FIGHT - Philadelphia (USA)

PP 5.7.4: Collaboration in Community Education: BEAT-HIV Community Engagement Group (CEG) and the HIV Cure Research Education Video Series
Author(s): L.J. Montaner 1,*, B. Peterson 1, W. Freshwater 2, C. White 2, M. Lefae 3, C. Roebuck 4, N. Jones 5, J. Shull 6, D.S. Metzger 7, J.L. Riley 7
1The Wistar Institute - Philadelphia (USA), 2BEAT-HIV CAB - Philadelphia (USA), 3AIDS Law Project - Philadelphia (USA), 4Cornell University - Ithaca (USA), 5Temple University - Philadelphia (USA), 6Philadelphia FIGHT - Philadelphia (USA), 7University of Pennsylvania - Philadelphia (USA)

PP 5.7.5: Behind the Scenes: Clinical and Rapid Autopsy Staff Members’ Experiences and Perceptions of HIV Reservoir Research at the End of Life
1HIV + Aging Research Project--Palm Springs - Palm Springs (USA), 2University of North Carolina - Chapel Hill (USA), 3University of California San Diego - La Jolla (USA), 4University of California San Diego - Chapel Hill (USA)

PP 5.7.6: Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
Author(s): M. Coiras 1, P. Martínez-Román 1,*, C. Crespo-Bermejo 1, A. Fernández-Rodríguez 1, V. Briz 1
1Institute of Health Carlos III - Majadahonda (SPA)

PP 5.7.7: HIV Particles Expressed in Semen under INSTI-based Suppressive Therapy are Largely Myeloid Cell-Derived and Exhibit Widely Diverse Genotypes
Author(s): J. Johnson 1,*, D. Anderson 2, J.F. Li 1, A. Santos Tino 3, J. Politch 2, J. Lipscomb 1, J. Defelice 4, M. Gelman 4, K. Mayer 4
1CDC - Atlanta (USA), 2BU School of Medicine - Boston (USA), 3The DESA Group - Atlanta (USA), 4The Fenway Institute - Boston (USA)

PP 5.7.8: Rapid ART in blood donors with Acute and Recent HIV clade C infection in South Africa
Author(s): E. Murphy 3,*, K. Van Den Berg 1,*, M. Vermeulen 1, S. Bakkour 2, M. Busch 1
1South African National Blood Service - Johannesburg (ZAF), 2Vitalant Research Institute - San Francisco (USA), 3UCSF and Vitalant Research Institute - San Francisco (USA)

PP 5.7.9: HIV-1 in the Latent Reservoir Is Largely Sensitive To Circulating T Cells
Author(s): J. Warren 1,*, S. Zhou 1, Y. Xu 1, M. Moeser 1, J. Kuruc 1, C. Gay 1, D. Margolis 1, N. Archin 1, R. Swanstrom 1, N. Goonetilleke 1
1University of North Carolina at Chapel Hill - Chapel Hill (USA)
PP 5.7.10: Analytical treatment interruption and rearrangement of HIV-1 drug resistance mutations in peripheral reservoir
Author(s): E. Bruzzi 1,*, R. Scutari 2, M.C. Bellocchi 2, V. Spagnuolo 3, L. Galli 4, L. Carioti 2, M.M. Santoro 2, C. Alteri 2, F. Ceccherini-Silberstein 2, A. Castagna 1
1Università Vita-Salute San Raffaele - Milan (ITA), 2Department of Experimental Medicine, University of Rome Tor Vergata - Rome (ITA), 3Università Vita-Salute San Raffaele - Milano (ITA), 4Infectious Diseases, San Raffaele Scientific Institute - Milan (ITA)

PP 5.7.11: Persistent HIV reservoir suppression by (-)-hopeaphenol, a plant-derived stilbenoid
Author(s): I. Tietjen 1,2,*, Z. Haq 2, M. Naidu 2, J. Rivera-Ortiz 1, Y. Cai 1, K. Beattie 3, T. Rali 4, Z. Brumme 2, L. Montaner 1, R. Davis 3
1The Wistar Institute - Philadelphia (USA), 2Simon Fraser University - Burnaby (CAN), 3Griffith University - Brisbane (Australia), 4University of Papua New Guinea - Port Moresby (Papua-nouvelle-guinée)

PP 5.7.12: Phorbol esters isolated from Croton megalobotrys reverse HIV latency ex vivo
Author(s): I. Tietjen 1,2,*, K. Richard 2, D. Williams 3, J. Rivera-Ortiz 1, Y. Cai 1, A. Pagliuzza 4, N. Chomont 4, R. Andersen 3, L. Montaner 1, K. Andrae-Marobela 5
1The Wistar Institute - Philadelphia (USA), 2Simon Fraser University - Burnaby (CAN), 3University of British Columbia - Vancouver (CAN), 4Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CR-CHUM) - Montreal (CAN), 5University of Botswana - Gaborone (Botswana)

PP 5.7.13: Targeting HIV-1-driven aberrant transcription and proliferation
Author(s): Y-C. Ho 1,*, Y.H. Yeh 1, K. Jenike 2
1Yale University - New Haven (USA), 2Johns Hopkins University - Baltimore (USA)

PP 5.7.14: A Mechanistic Modeling Platform for HIV Cure Drug Development
Author(s): Y. Cao 1,*, D. Rosenbloom 1,*, M. Ahamadi 1, S. Bae 1, R. Vargo 1
Merck & Co., Inc. - Kenilworth, Nj (USA)

PP 5.7.15: In vitro demonstration of a potential role for STING agonist in HIV cure
Author(s): A. Koblansky 1,2,*, S. Raines 2, J. Schawalder 1, D. Irlbeck 1, C. Galardi 1, J. Brehm 1, J. Ramanjulu 3, D. Margolis 2, H. Madsen 1
1ViiV Healthcare - Chapel Hill (USA), 2UNC HIV Cure Center - Chapel Hill (USA), 3GlaxoSmithKline - Upper Providence (USA)

PP 5.7.16: Enhancing antiretroviral drug penetration into lymph nodes through intramuscular and subcutaneous routes of administration in BALB/c mice
Author(s): S. Dyavar 1,*
UNMC - Nebraska (USA)
PP 6.8.1: Targeting lncRNA SAF to induce apoptosis in HIV-1 infected macrophages
Author(s): S. Boliar 1,* , D.W. Gludish 1, K.C. Jambo 1, H.C. Mwandumba 2, D.G. Russell 1
1Cornell University - Ithaca (USA), 2University of Malawi - Blantyre (Malawi)

PP 6.8.2: Blocking TIM-3 reinvigorates exhausted CD8 T cells with no impact on NK cell function in ART-treated HIV-infected patients
Author(s): C. Gutiérrez 1,* , M. Sanz 1, N. Madrid-Elena 1, S. Serrano-Villar 1, S. Moreno 1,*
Infectious Diseases Department, Ramón y Cajal Hospital - Madrid (SPA)

PP 6.8.3: Isolation of monoclonal antibodies targeting HLA-E-HIV-1 and SIV peptide complexes
Author(s): D. Li 1,* , S. Brackenridge 2, M. Tuyishime 3, D. Cain 1, Z. Mu 1, B. Mattia 1, G. Ferrari 3, G. Geraldine 7, A. Mcmichael 2, B. Haynes 1
1Department of Surgery, Duke University Medical Center - Durham (USA), 2UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill - Chapel Hill (USA),
3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill - Chapel Hill (USA),
4Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center - Durham (USA), 5Departments of Microbiology and Immunology, and Epidemiology, University of North Carolina at Chapel Hill - Chapel Hill (USA)

PP 6.8.4: Improved Killing of HIV-infected Cells by a Combination of Three Antibodies: implications for clearing persistent infection
Author(s): M. Tuyishime 1,* , C. Garrido 2, S. Jha 1, D. Mielke 1, M. Moeser 3, B. Haynes 4, S. Joseph 3, D. Margolis 7, G. Ferrari 1
1Department of Surgery, Duke University Medical Center - Durham (USA), 2UNC HIV Cure Center and Department of Medicine, University of North Carolina at Chapel Hill - Chapel Hill (USA),
3Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill - Chapel Hill (USA),
4Duke Human Vaccine Institute, Department of Medicine, Duke University Medical Center - Durham (USA), 5Departments of Microbiology and Immunology, and Epidemiology, University of North Carolina at Chapel Hill - Chapel Hill (USA)

PP 6.8.5: Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
Author(s): S. Moreno 1,* , M. López Huertas 1,* , L. Jiménez Tormo 1, N. Madrid Elena 1, C. Gutiérrez 1, M.J. Vivancos 1, L. Luna 1
Instituto Ramón y Cajal de Investigación Sanitaria. - Madrid (SPA)

PP 6.8.6: Modulated Production of Endogenous Anti-HIV Broadly Neutralizing Antibodies
Author(s): Y. Gao 1,* , D. Patel 2, C. Ding 1, Y. Ma 2, W. Li 1, R. Dekoter 2
1The First Affiliated Hospital, University of Science and Technology of China - Hefei (CHI), 2Department of Microbiology and Immunology, Schullich School of Medicine and Dentistry, The University of Western Ontario - London (CAN)

PP 6.8.7: CD4+ T cells from patients with chronic myeloid leukemia are resistant to HIV-1 proviral integration and transcription after prolonged withdrawal of treatment with tyrosine kinase inhibitors
Author(s): M. Coiras 1,* , L. Vigón 1, S. Rodríguez-Mora 1, V. García-Gutierrez 2, J. Ambrosioni 3, J. Alcamí 3, J.L. Steegmann 6, J. Alcamí 1, J.M. Miro 3, V. García 3, N. Climent 4, G. Bautista 5, M. Plana 4, B. Haynes 1
1AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III - Madrid (SPA),
2Hematology Service, Hospital Universitario Ramón y Cajal - Madrid (SPA),
3Infectious Diseases Service, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona - Barcelona (SPA),
4Retrovirology and Viral Immunopathology Laboratory, IDIBAPS, Hospital Clinic, University of Barcelona - Barcelona (SPA),
5Hematology Service, Hospital Universitario Puerta de Hierro - Madrid (SPA),
6Hematology Service, Hospital Universitario La Princesa, Madrid (SPA),
7Division of Microbiology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City - Utah (USA)

PP 6.8.8: Antagonism of PPARγ for Th17 Mucosal Immunity Restoration and HIV Reservoir Purging
Author(s): D. Planas 1,* , A. Fert 1,* , Y. Zhang 1, M.J. Ruiz 1, J.P. Goulet 2, T.R. Wiche Salinas 1, E.A. Cohen 3, J.P. Routy 3, N. Chomont 1, P. Ancuta 1
1Centre de recherche du CHUM - Montréal (CAN), 2Caprion - Montréal (CAN), 3Institut de Recherches Cliniques de Montréal - Montréal (CAN), 4McGill University - Montréal (CAN)

PP 6.8.9: Targeting STAT SUMOylation to enhance NK cell cytotoxicity
Author(s): A. Macedo 1,* , C. Levinger 1, A. C. Hernandez Santini 2, N. Bonan 1, B. Nguyen 1, K. Crandall 1, R. Lynch 1, A. Bosque 1, A. George Washington University - Washington (USA), 2University of Puerto Rico - Ponce (PRI)

PP 6.8.10: Broad-spectrum gRNAs abolish HIV-1 LTR-mediated transcription in cells that receive CRISPR/Cas9 therapy
Author(s): S. Wigdahl 1,* , A. Allen 1,* , S. Worell 1, G. Nwaozo 1, R. Madrid 1, W. Dampier 1, M. Nonnemacher Drexel University College of Medicine - Philadelphia (USA)
PP 6.8.11: CRISPR/Cas9 editing of HIV-1 transcription factor binding sites on the 5’ long terminal repeats to permanently inactivate latent provirus
Author(s): B. Wigdahl 1,* , C-H. Chung 1,* , A.G. Allen 1, A.J. Atkins 1, R. Costello 1, N.T. Sullivan 1, M.R. Nonnemacher 1, W.N. Dampier 1
Drexel University - Philadelphia (USA)

Author(s): W. Hu 1,*, Y. Zhu 1,*, E. Bouikidis 1, F. Li 1, Y. Lin 1, Y. Cai 2, H. Wang 1, L. Montaner 2, W. Ho 1, S. Turville 3
1Temple University School of Medicine - Philadelphia (USA), 2Wistar Institute - Philadelphia (USA), 3University of New South Wales (UNSW) - Sydney (Australie)

PP 6.8.13: Block and kill: a new approach to prevent HIV reactivation, reduce immune activation, induce apoptosis of infected cells
Author(s): A. Garzino Demo 1,* , S. Lingling 2, C. Cairo 3, T.W. Chun 4, M.K. Lafferty 3
1,2,3Institute of Human Virology, University of Maryland School of Medicine - Baltimore (USA), 4National Institute of Allergy and Infectious Diseases, National Institutes of Health - Bethesda (USA)

PP 6.8.14: HIV-1 diversity considerations for clinical studies of passively transferred broadly neutralizing antibodies
Author(s): K. Wag 1,* , K. Stephenson 2, D. Barouch 2, B. Korber 1
1Theoretical Biology & Biophysics, Los Alamos National Laboratory - Los Alamos (USA), 2Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center - Boston (USA)

PP 6.8.15: Cleaving HIV-1 Provirus from ART-Suppressed Patient-derived Resting CD4+ T Cells Using Cpf1/crRNA-array Ribonucleotide Protein Packaged by CD4-targeting Lentivirus-like Particle
Author(s): W. Hu 2,* , Y. Cai 1, Y. Zhu 2, F. Li 2, A.O. Stella 3, P. Tebas 4, K. Mounzer 5, J. Kostman 5, S. Turville 3, L. Montaner 1
1HIV-1 Immunopathogenesis Laboratory, The Wistar Institute - Philadelphia (USA), 2Department of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medici - Philadelphia (USA), 3The Kirby Institute, University of New South Wales (UNSW) - Sydney (Australie), 4Perelman School of Medicine, University of Pennsylvania - Philadelphia (USA), 5Philadelphia Field Initiating Group for HIV-1 Trials - Philadelphia (USA)

PP 6.8.16: A bispecific antibody that simultaneously recognizes the V2- and V3-glycan epitopes of the HIV-1 envelope glycoprotein
Author(s): M. Davis-Gardner 1,* , M. Gardner 1, M. Farzan 1
The Scripps Research Institute - Jupiter (USA)

PP 6.8.17: Exploring Sequence Specific Silencing of Latent HIV Using CRISPR Interference
Author(s): R. Schwarzer 1,* , M. Montano 1, W.C. Greene 1
Gladstone Center for HIV Cure Research - San Francisco (USA)

PP 6.8.18: Enhancement of antibody-dependent cellular phagocytosis is essential to the clearance of HIV-1 reservoirs in lymphoid organs
Author(s): L. Shan 1,*
Washington University - St. Louis (USA)

PP 6.8.19: Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 Long Terminal repeat
Author(s): C. Li 1,* , S. Valente 1,* , G. Mousseau 1
The Scripps research Institute - Jupiter (USA)

PP 6.8.20: Resistance to the Tat inhibitor didehydro-Cortistatin A is mediated by heightened basal HIV-1 transcription
Author(s): S. Mediouni 1,* , S. Valente 1
The Scripps research Institute - Jupiter (USA)

PP 6.8.21: HLA-E-presented peptides as novel targets for HIV-1 therapy
Author(s): S. Brackenridge 1,* , H. Yang 1, D. Li 2, G. Gillespie 1, B. Haynes 2, A. Mcmichael 1
1University of Oxford - Oxford (United Kingdom), 2Duke University - Durham (USA)

PP 6.8.22: Development of anti-PD-1 chimeric antigen receptor T cells to target a PD-1+ CD4 T cell population enriched in HIV provirus
Author(s): K. Eichholz 1,* , F. Haeseleer 2, L. Corey 3
1VIDD, Fred Hutchinson Cancer Research Center - Seattle (USA), 2Departments of Laboratory Medicine and Medicine, University of Washington - Seattle (USA), 3Departments of Laboratory Medicine and Medicine, University of Washington, VIDD, Fred Hutchinson Cancer Research Center - Seattle (USA)

PP 6.8.23: Conditions for post-rebound SHIV control in autologous hematopoietic-stem cell transplantation
Author(s): F. Cardozo 1,* , E. Duke 1, C. Peterson 1, D. Reeves 1, B. Mayer 1, H.P. Kiem 1,2, J. Schiffer 3
1Fred Hutchinson Cancer Research Center - Seattle, Wa (USA), 2University of Washington - Seattle, WA (USA), 3Fred Hutchinson Cancer Research Center/University of Washington - Seattle, WA (USA)
POSTER AREA
Poster presenters are asked to stand next to their poster during the wine & cheese tasting (times indicated below):

Wednesday, December 11: 4:00 – 7:00 PM
Thursday, December 12: 4:00 – 7:00 PM

POSTER TOPICS

Basic science of HIV latency
In vitro and animal models studies of the persistence
Virology of HIV persistence
Immunology of HIV persistence
Human studies and drug development I & II
New therapeutic approaches I & II

The selected abstracts will benefit from a high visibility thanks to their presentation into the open access scientific Journal of Virus Eradication from December 10, 2019.

Please connect to www.viruseradication.com to read the abstracts

COFFEE BREAKS

Tuesday, December 10: 3:30 – 4:00 PM
Wednesday, December 11: 10:00 – 10:30 AM
Thursday, December 12: 10:00 – 10:30 AM
Friday, December 13: 10:00 – 10:30 AM
GENERAL INFORMATION

LOGISTIC ORGANIZATION & REGISTRATION
OVERCOME: 13-15 rue des Sablons, 75116 Paris, France
Tel: +33 (0)1 40 88 97 97 - Email: hivpersistence@overcome.fr

CONGRESS VENUE
MARRIOTT BISCAYNE BAY HOTEL
1633 North Bayshore Drive, Miami, FL 33132, Florida, United States of America
Phone: +1 305-374-3900

WORKSHOP OPENING HOURS
• Tuesday, December 10: 8:00 AM - 7:30 PM
• Wednesday, December 11: 7:45 AM - 7:00 PM
• Thursday, December 12: 7:45 AM - 7:00 PM
• Friday, December 13: 7:45 AM - 2:00 PM

WORKSHOP OBJECTIVES
Provide an opportunity for scientist experts on HIV reservoirs to share ideas and debate in order to develop and increase knowledge to help for future research:
• Provide a place for network and information-sharing between scientists specialized in the reservoir
• Present state-of-the-art basic science and clinical researches on HIV therapy with unpublished data and have a panel of experts to sum up the current advances in the field
• Accelerate research on reservoirs and latency to find a cure

BADGES & CERTIFICATE OF ATTENDANCE
• Certificate of attendance
  Certificate of attendance will be sent by email after the week after the workshop.
• Badges
  The name badges must be worn at all times during the workshop and is non transferable. Access to the conference will not be granted without an official conference name badge.

LANGUAGE
All sessions will be held in English

COFFEE BREAKS
Coffee will be served free of charge in the catering area of the workshop on level 3 to all registrated delegates during the following times:
• Tuesday, December 10: 3:30 - 4:00 PM
• Wednesday, December 11: 10:00 - 10:30 AM
• Thursday, December 12: 10:00 - 10:30 AM
• Friday, December 13: 10:00 - 10:30 AM
LUNCH & DINNER

Lunch will be served free of charge in a dedicated room on level 2 - in Watson Island room/Bayview Ballroom if the weather is bad or in the Bayfront Terrace if the weather is fine - as follows:

Lunch:
- Wednesday, December 10: 4.00 - 7.00 PM
- Thursday December 11: 4.00 - 7.00 PM

WELCOME DINNER:
- Tuesday, December 10: 7:30 - 11:30 PM
At Briza on the Bay, 1717 N. Bayshore Drive Suite #115, Miami, FL 33132
One minute walk - 20 steps from the Marriott!
Meeting point: Marriott Biscayne bay hotel’s lobby at 7:30 PM. Prior registration is required.

ABSTRACT BOOK

All accepted abstracts will be published in the online abstract book. It will be available on the Journal of Virus Eradication website: www.viruseradication.com

POSTER AREA

Poster area is located in level 3, close to the conference room.

Poster authors will be asked to be present next to their poster during the poster viewing session during the following times:
- Wednesday, December 10: 4:00 - 7:00 PM
- Thursday, December 11: 4:00 - 7:00 PM

PREVIEW FOR SPEAKERS AND ORAL PRESENTERS

Invited speakers and oral abstract presenters must report to the Preview desk situated at the back of the plenary room at least 3 hours prior to their presentation to upload and check their presentation. For a morning presentation, please report to preview desk the day before until 6:00 PM.

TRANSPORTATION

Event ID: 34206AF
Validity: from December 8, 2019 to December 18, 2019.
Call for Papers: Volume 6

We are seeking papers for issues in 2020 and can offer the following advantages:

- Published quarterly
- Available online or through PMC
- High-quality content, vigorously peer reviewed
- New improved submission system and short submission to publication times
- Fast-track pathway to publish work in HIV, HBV, HCV, other viral infections including HPV, polio, herpes, flu, Ebola, Zika and coronavirus
- Eminent international Editorial Board and Panel
- Embracing papers on epidemiological, immunological, virological, pharmacological, preclinical, clinical and in vitro research
- Open-access journal entering its sixth year
- Online portal for abstract supplements – find published supplements on PMC
- Readership: growing international community involved in the prevention and management of viral infections
- Partnership with Australasian Society for HIV, Viral Hepatitis and Sexual Health (ASHM)

<table>
<thead>
<tr>
<th>Issue</th>
<th>Copy date</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>16th October 2019</td>
</tr>
<tr>
<td>6.2</td>
<td>10th January 2020</td>
</tr>
<tr>
<td>6.3</td>
<td>10th April 2020</td>
</tr>
<tr>
<td>6.4</td>
<td>10th July 2020</td>
</tr>
</tbody>
</table>
The National Institute of Allergy and Infectious Diseases (NIAID) will host the fifth biennial *Strategies for an HIV Cure meeting* at the NIH main campus in Bethesda, MD on **November 16-18, 2020**. The goal of the meeting is to highlight state-of-the-art research in the field and facilitate communication and collaboration among NIAID-funded researchers, the broader HIV cure research community, and community stakeholders. The meeting will serve as the joint meeting of the Martin Delaney Collaboratories for 2020. Registration is free, and poster abstracts are encouraged.

Information on the 2018 meeting, as well as video links to presentations can be found at: [https://www.cvent.com/events/strategies-for-an-hiv-cure-2018/event-summary-67d64e8621247079e009b4757f45c9e.aspx](https://www.cvent.com/events/strategies-for-an-hiv-cure-2018/event-summary-67d64e8621247079e009b4757f45c9e.aspx)

NIAID will also convene researchers supported by its *Understanding HIV Rebound* program for a one-day workshop in Rockville, MD on **Monday, April 20th, 2020**. Registration for this workshop will also be free and open to the public.

We look forward to seeing you next year in Maryland!

Diane Lawrence
David McDonald
Leia Novak
Eric Refsland
Karl Salzwedel

---

The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services (HHS), nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PERSISTENCE.
IT’S WHY WE’RE [STILL] HERE.

ADVANCING AIDS RESEARCH FOR MORE THAN 30 YEARS
COMMITTED TO A CURE

For information contact grants@amfar.org

amfAR
MAKING AIDS HISTORY